

METLIFE INC
Form 10-Q
August 07, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-15787

MetLife, Inc.

(Exact name of registrant as specified in its charter)

Delaware 13-4075851
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

200 Park Avenue, New York, N.Y. 10166-0188

(Address of principal executive offices) (Zip Code)

(212) 578-9500

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

At July 31, 2018, 994,837,941 shares of the registrant's common stock, \$0.01 par value per share, were outstanding.

Table of Contents

	Page
<u>Part I — Financial Information</u>	
Item 1. Financial Statements (at June 30, 2018 and December 31, 2017 (Unaudited) and for the Three Months and Six Months Ended June 30, 2018 and 2017 (Unaudited))	
<u>Interim Condensed Consolidated Balance Sheets</u>	<u>3</u>
<u>Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</u>	<u>4</u>
<u>Interim Condensed Consolidated Statements of Equity</u>	<u>5</u>
<u>Interim Condensed Consolidated Statements of Cash Flows</u>	<u>6</u>
<u>Notes to the Interim Condensed Consolidated Financial Statements:</u>	
<u>Note 1 — Business, Basis of Presentation and Summary of Significant Accounting Policies</u>	<u>7</u>
<u>Note 2 — Segment Information</u>	<u>13</u>
<u>Note 3 — Dispositions</u>	<u>21</u>
<u>Note 4 — Insurance</u>	<u>27</u>
<u>Note 5 — Closed Block</u>	<u>29</u>
<u>Note 6 — Investments</u>	<u>32</u>
<u>Note 7 — Derivatives</u>	<u>46</u>
<u>Note 8 — Fair Value</u>	<u>63</u>
<u>Note 9 — Long-Term Debt</u>	<u>83</u>
<u>Note 10 — Equity</u>	<u>83</u>
<u>Note 11 — Other Expenses</u>	<u>90</u>
<u>Note 12 — Employee Benefit Plans</u>	<u>91</u>
<u>Note 13 — Income Tax</u>	<u>92</u>
<u>Note 14 — Earnings Per Common Share</u>	<u>93</u>
<u>Note 15 — Contingencies, Commitments and Guarantees</u>	<u>94</u>
<u>Note 16 — Subsequent Events</u>	<u>101</u>
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>102</u>
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>183</u>
Item 4. <u>Controls and Procedures</u>	<u>184</u>
 <u>Part II — Other Information</u>	
Item 1. <u>Legal Proceedings</u>	<u>185</u>
Item 1A. <u>Risk Factors</u>	<u>185</u>
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>187</u>
Item 6. <u>Exhibits</u>	<u>188</u>
 <u>Signatures</u>	 <u>190</u>

Table of Contents

As used in this Form 10 Q, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates.

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10 Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will,” and other words and terms of similar meaning, or are tied to future performance in connection with a discussion of future performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results. Many factors will be important in determining the results of MetLife, Inc., its subsidiaries and affiliates.

Forward-looking statements are based on our assumptions and current expectations, which may be inaccurate, and on the current economic environment, which may change. These statements are not guarantees of future performance. They involve a number of risks and uncertainties that are difficult to predict. Results could differ materially from those expressed or implied in the forward-looking statements. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission. These factors include: (1) adverse effects which may arise in connection with the material weaknesses in our internal control over financial reporting or our failure to promptly remediate them; (2) difficult conditions in the global capital markets; (3) increased volatility and disruption of the global capital and credit markets, which may affect our ability to meet liquidity needs and access capital, including through our credit facilities, generate fee income and market-related revenue and finance statutory reserve requirements and may require us to pledge collateral or make payments related to declines in value of specified assets, including assets supporting risks ceded to certain of our captive reinsurers or hedging arrangements associated with those risks; (4) exposure to global financial and capital market risks, including as a result of the United Kingdom’s notice of withdrawal from the European Union or other disruption in global political, security or economic conditions; (5) impact on us of comprehensive financial services regulation reform; (6) numerous rulemaking initiatives required or permitted by the Dodd-Frank Wall Street Reform and Consumer Protection Act which may impact how we conduct our business, including those compelling the liquidation of certain financial institutions; (7) regulatory, legislative or tax changes relating to our insurance, international, or other operations that may affect the cost of, or demand for, our products or services, or increase the cost or administrative burdens of providing benefits to employees; (8) adverse results or other consequences from litigation, arbitration or regulatory investigations; (9) potential liquidity and other risks resulting from our participation in a securities lending program and other transactions; (10) investment losses and defaults, and changes to investment valuations; (11) changes in assumptions related to investment valuations, deferred policy acquisition costs, deferred sales inducements, value of business acquired or goodwill; (12) impairments of goodwill and realized losses or market value impairments to illiquid assets; (13) defaults on our mortgage loans; (14) the defaults or deteriorating credit of other financial institutions that could adversely affect us; (15) economic, political, legal, currency and other risks relating to our international operations, including with respect to fluctuations of exchange rates; (16) downgrades in our claims paying ability, financial strength or credit ratings; (17) a deterioration in the experience of the closed block established in connection with the reorganization of Metropolitan Life Insurance Company; (18) availability and effectiveness of reinsurance, hedging or indemnification arrangements, as well as any default or failure of counterparties to perform; (19) differences between actual claims experience and underwriting and reserving assumptions; (20) ineffectiveness of risk management policies and procedures; (21) catastrophe losses; (22) increasing cost and limited market capacity for statutory life insurance reserve financings; (23) heightened competition, including with respect to pricing, entry of new competitors, consolidation of distributors, the development of new products by new and existing competitors, and for personnel; (24) exposure to losses related to variable annuity guarantee benefits, including from significant and sustained downturns or extreme volatility in equity markets, reduced interest rates, unanticipated policyholder behavior, mortality or longevity, and any adjustment for

nonperformance risk; (25) our ability to address difficulties, unforeseen liabilities, asset impairments, or rating agency actions arising from (a) business acquisitions and integrating and managing the growth of such acquired businesses, (b) dispositions of businesses via sale, initial public offering, spin-off or otherwise, including failure to achieve projected operational benefit from such transactions and any restrictions, liabilities, losses or indemnification obligations arising from any transitional services or tax arrangements related to the separation of any business, or from the failure of such a separation to qualify for any intended tax-free treatment, (c) entry into joint ventures, or (d) legal entity reorganizations; (26) unanticipated or adverse developments that could adversely affect our achieving expected operational or other benefits from the separation of Brighthouse Financial, Inc. and its subsidiaries (“Brighthouse”); (27) liabilities, losses or indemnification obligations arising from our transitional services, investment management or tax arrangements or other agreements with Brighthouse; (28) failure of the separation of Brighthouse to qualify for intended tax-free treatment; (29) legal, regulatory and other restrictions affecting MetLife, Inc.’s ability to pay dividends and repurchase common stock; (30) MetLife, Inc.’s and its subsidiary holding companies’ primary reliance, as holding companies, on dividends from subsidiaries to meet free cash flow targets and debt payment obligations and the applicable regulatory restrictions on the ability of the subsidiaries to pay such dividends; (31) the possibility that MetLife, Inc.’s Board of Directors may influence the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; (32) changes in accounting standards, practices and/or policies; (33) increased expenses relating to pension and postretirement benefit plans, as well as health care and other employee benefits; (34) inability to protect our intellectual property rights or claims of infringement of the intellectual property rights of others; (35) difficulties in marketing and distributing products through our distribution channels; (36) provisions of laws and our incorporation documents that may delay, deter or prevent takeovers and corporate combinations involving MetLife; (37) the effects of business disruption or economic contraction due to disasters such as terrorist attacks, cyberattacks, other hostilities, or natural catastrophes, including any related impact on the value of our investment portfolio, our disaster recovery systems, cyber- or other information security systems and management continuity planning; (38) any failure to protect the confidentiality of client information; (39) the effectiveness of our programs and practices in avoiding giving our associates incentives to take excessive risks; (40) the impact of technological changes on our businesses; and (41) other risks and uncertainties described from time to time in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in reports to the U.S. Securities and Exchange Commission.

Corporate Information

We announce financial and other information about MetLife to our investors through the MetLife Investor Relations web page at www.metlife.com, as well as U.S. Securities and Exchange Commission filings, news releases, public conference calls and webcasts. MetLife encourages investors to visit the Investor Relations web page from time to time, as information is updated and new information is posted. The information found on our website is not incorporated by reference into this Quarterly Report on Form 10-Q or in any other report or document we file with the U.S. Securities and Exchange Commission, and any references to our website are intended to be inactive textual references only.

Note Regarding Reliance on Statements in Our Contracts

See “Exhibits — Note Regarding Reliance on Statements in Our Contracts” for information regarding agreements included as exhibits to this Quarterly Report on Form 10-Q.

Table of Contents

Part I — Financial Information

Item 1. Financial Statements

MetLife, Inc.

Interim Condensed Consolidated Balance Sheets

June 30, 2018 and December 31, 2017 (Unaudited)

(In millions, except share and per share data)

	June 30, 2018	December 31, 2017
Assets		
Investments:		
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: \$292,257 and \$286,069, respectively)	\$ 306,331	\$ 308,931
Equity securities, at estimated fair value	1,483	2,513
Contractholder-directed equity securities and fair value option securities, at estimated fair value (includes \$5 and \$6, respectively, relating to variable interest entities)	13,848	16,745
Mortgage loans (net of valuation allowances of \$325 and \$314, respectively; includes \$405 and \$520, respectively, under the fair value option)	70,852	68,731
Policy loans	9,702	9,669
Real estate and real estate joint ventures (includes \$630 and \$25, respectively, of real estate held-for-sale)	9,741	9,637
Other limited partnership interests	5,985	5,708
Short-term investments, principally at estimated fair value	3,853	4,870
Other invested assets (includes \$453 and \$125, respectively, relating to variable interest entities)	17,017	17,263
Total investments	438,812	444,067
Cash and cash equivalents, principally at estimated fair value (includes \$11 and \$12, respectively, relating to variable interest entities)	16,312	12,701
Accrued investment income	3,512	3,524
Premiums, reinsurance and other receivables (includes \$2 and \$3, respectively, relating to variable interest entities)	19,608	18,423
Deferred policy acquisition costs and value of business acquired	19,013	18,419
Goodwill	9,499	9,590
Other assets (includes \$2 and \$2, respectively, relating to variable interest entities)	8,230	8,167
Separate account assets	191,347	205,001
Total assets	\$ 706,333	\$ 719,892
Liabilities and Equity		
Liabilities		
Future policy benefits	\$ 184,461	\$ 177,974
Policyholder account balances	182,493	182,518
Other policy-related balances	15,908	15,515
Policyholder dividends payable	695	682
Policyholder dividend obligation	792	2,121
Payables for collateral under securities loaned and other transactions	27,030	25,723
Short-term debt	479	477
Long-term debt (includes \$5 and \$6, respectively, at estimated fair value, relating to variable interest entities)	14,536	15,686
Collateral financing arrangement	1,085	1,121
Junior subordinated debt securities	3,146	3,144

Edgar Filing: METLIFE INC - Form 10-Q

Current income tax payable	222	311
Deferred income tax liability	5,377	6,767
Other liabilities (includes \$1 and \$3, respectively, relating to variable interest entities)	24,930	23,982
Separate account liabilities	191,347	205,001
Total liabilities	652,501	661,022
Contingencies, Commitments and Guarantees (Note 15)		
Equity		
MetLife, Inc.'s stockholders' equity:		
Preferred stock, par value \$0.01 per share; \$3,405 and \$2,100 aggregate liquidation preference, respectively	—	—
Common stock, par value \$0.01 per share; 3,000,000,000 shares authorized; 1,170,816,195 and 1,168,710,101 shares issued, respectively; 1,000,153,999 and 1,043,588,396 shares outstanding, respectively	12	12
Additional paid-in capital	32,454	31,111
Retained earnings	26,870	26,527
Treasury stock, at cost; 170,662,196 and 125,121,705 shares, respectively	(8,557)	(6,401)
Accumulated other comprehensive income (loss)	2,854	7,427
Total MetLife, Inc.'s stockholders' equity	53,633	58,676
Noncontrolling interests	199	194
Total equity	53,832	58,870
Total liabilities and equity	\$706,333	\$ 719,892

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

For the Three Months and Six Months Ended June 30, 2018 and 2017 (Unaudited)

(In millions, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,		
	2018	2017	2018	2017	
Revenues					
Premiums	\$15,153	\$9,580	\$24,331	\$18,545	
Universal life and investment-type product policy fees	1,370	1,364	2,762	2,724	
Net investment income	4,473	4,193	8,218	8,614	
Other revenues	475	292	949	634	
Net investment gains (losses)	(227)	104	(560)	192	
Net derivative gains (losses)	(59)	(200)	290	(412)	
Total revenues	21,185	15,333	35,990	30,297	
Expenses					
Policyholder benefits and claims	14,866	9,427	23,584	18,290	
Interest credited to policyholder account balances	1,424	1,292	2,193	2,743	
Policyholder dividends	309	313	606	623	
Other expenses	3,485	3,283	6,850	6,551	
Total expenses	20,084	14,315	33,233	28,207	
Income (loss) from continuing operations before provision for income tax	1,101	1,018	2,757	2,090	
Provision for income tax expense (benefit)	207	162	606	282	
Income (loss) from continuing operations, net of income tax	894	856	2,151	1,808	
Income (loss) from discontinued operations, net of income tax	—	58	—	(18)	
Net income (loss)	894	914	2,151	1,790	
Less: Net income (loss) attributable to noncontrolling interests	3	3	7	6	
Net income (loss) attributable to MetLife, Inc.	891	911	2,144	1,784	
Less: Preferred stock dividends	46	46	52	52	
Net income (loss) available to MetLife, Inc.'s common shareholders	\$845	\$865	\$2,092	\$1,732	
Comprehensive income (loss)	\$(1,885)	\$2,953	\$(3,333)	\$4,860	
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax	4	2	8	6	
Comprehensive income (loss) attributable to MetLife, Inc.	\$(1,889)	\$2,951	\$(3,341)	\$4,854	
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.'s common shareholders:					
Basic		\$0.83	\$0.76	\$2.04	\$1.62
Diluted		\$0.83	\$0.75	\$2.02	\$1.61
Net income (loss) available to MetLife, Inc.'s common shareholders per common share:					
Basic		\$0.83	\$0.81	\$2.04	\$1.60
Diluted		\$0.83	\$0.80	\$2.02	\$1.59
Cash dividends declared per common share		\$0.420	\$0.400	\$0.820	\$0.800

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Equity

For the Six Months Ended June 30, 2018 and 2017 (Unaudited)

(In millions)

	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock at Cost	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc. Stockholders' Equity	Noncontrol- ling Interests	Total Equity
Balance at December 31, 2017	\$ —	\$ 12	\$ 31,111	\$ 26,527	\$ (6,401)	\$ 7,427	\$ 58,676	\$ 194	\$ 58,870
Cumulative effects of changes in accounting principles, net of income tax (Note 1)				(905)		912	7		7
Balance at January 1, 2018	—	12	31,111	25,622	(6,401)	8,339	58,683	194	58,877
Preferred stock issuance			1,274				1,274		1,274
Treasury stock acquired in connection with share repurchases					(2,156)		(2,156)		(2,156)
Stock-based compensation			69				69		69
Dividends on preferred stock				(52)			(52)		(52)
Dividends on common stock				(844)			(844)		(844)
Change in equity of noncontrolling interests							—	(3)	(3)
Net income (loss)				2,144			2,144	7	2,151
Other comprehensive income (loss), net of income tax						(5,485)	(5,485)	1	(5,484)
Balance at June 30, 2018	\$ —	\$ 12	\$ 32,454	\$ 26,870	\$ (8,557)	\$ 2,854	\$ 53,633	\$ 199	\$ 53,832
	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock at Cost	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc.'s Stockholders' Equity	Noncontrol- ling Interests	Total Equity
Balance at December 31, 2016, as previously reported	\$ —	\$ 12	\$ 30,944	\$ 34,480	\$ (3,474)	\$ 5,347	\$ 67,309	\$ 171	\$ 67,480
Prior period revisions (Note 1)				203		19	222		222
Balance at December 31, 2016	—	12	30,944	34,683	(3,474)	5,366	67,531	171	67,702
Treasury stock acquired in connection with share repurchases					(1,810)		(1,810)		(1,810)
Stock-based compensation			77				77		77
Dividends on preferred stock				(52)			(52)		(52)
Dividends on common stock				(868)			(868)		(868)

Edgar Filing: METLIFE INC - Form 10-Q

Change in equity of noncontrolling interests						—	37	37		
Net income (loss)		1,784				1,784	6	1,790		
Other comprehensive income (loss), net of income tax				3,070		3,070	—	3,070		
Balance at June 30, 2017	\$	—	\$ 12	\$ 31,021	\$ 35,547	\$ (5,284)	\$ 8,436	\$ 69,732	\$ 214	\$ 69,946

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2018 and 2017

(Unaudited)

(In millions)

	Six Months Ended June 30,	
	2018	2017
Net cash provided by (used in) operating activities	\$6,904	\$5,499
Cash flows from investing activities		
Sales, maturities and repayments of:		
Fixed maturity securities	54,497	47,120
Equity securities	280	452
Mortgage loans	4,341	4,354
Real estate and real estate joint ventures	422	490
Other limited partnership interests	337	689
Purchases of:		
Fixed maturity securities	(58,061)	(49,995)
Equity securities	(64)	(616)
Mortgage loans	(6,380)	(7,126)
Real estate and real estate joint ventures	(495)	(602)
Other limited partnership interests	(568)	(682)
Cash received in connection with freestanding derivatives	2,376	3,945
Cash paid in connection with freestanding derivatives	(2,638)	(5,698)
Net change in policy loans	(42)	6
Net change in short-term investments	1,055	914
Net change in other invested assets	164	(206)
Other, net	12	(194)
Net cash provided by (used in) investing activities	(4,764)	(7,149)
Cash flows from financing activities		
Policyholder account balances:		
Deposits	46,858	44,854
Withdrawals	(44,976)	(42,387)
Net change in payables for collateral under securities loaned and other transactions	1,633	1,205
Long-term debt issued	14	2,989
Long-term debt repaid	(200)	(9)
Collateral financing arrangements repaid	(36)	(2,836)
Financing element on certain derivative instruments and other derivative related transactions, net	12	(94)
Treasury stock acquired in connection with share repurchases	(2,156)	(1,810)
Preferred stock issued, net of issuance costs	1,274	—
Dividends on preferred stock	(52)	(52)
Dividends on common stock	(844)	(868)
Other, net	85	(186)
Net cash provided by (used in) financing activities	1,612	806
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	(141)	286
Change in cash and cash equivalents	3,611	(558)
Cash and cash equivalents, beginning of period	12,701	17,877
Cash and cash equivalents, end of period	\$16,312	\$17,319

Edgar Filing: METLIFE INC - Form 10-Q

Cash and cash equivalents, of disposed subsidiary, beginning of period	\$—	\$5,226
Cash and cash equivalents, of disposed subsidiary, end of period	\$—	\$4,443
Cash and cash equivalents, from continuing operations, beginning of period	\$12,701	\$12,651
Cash and cash equivalents, from continuing operations, end of period	\$16,312	\$12,876
Supplemental disclosures of cash flow information		
Net cash paid (received) for:		
Interest	\$592	\$574
Income tax	\$577	\$505
Non-cash transactions:		
Fixed maturity securities received in connection with pension risk transfer transaction	\$3,016	\$—
Brighthouse common stock exchange transaction (Note 3):		
Reduction of long-term debt	\$944	\$—
Reduction of fair value option securities	\$1,030	\$—

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MetLife Holdings.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.

The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2017 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2017 Annual Report.

Consolidation

The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has control, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.

The Company uses the equity method of accounting for equity securities when it has significant influence or at least 20% interest and for real estate joint ventures and other limited partnership interests (“investees”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Subsequent to the adoption of guidance relating to the recognition and measurement of financial instruments on January 1, 2018, the Company accounts for interests in unconsolidated entities that are not accounted for under the equity method, at estimated fair value. Such investments were previously accounted for under the cost method of accounting. See “— Adoption of New Accounting Pronouncements.”

Discontinued Operations

The results of operations of a component of the Company that has either been disposed of or is classified as held-for-sale are reported in discontinued operations if certain criteria are met. A disposal of a component is reported in discontinued operations if the disposal represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.

On August 4, 2017, MetLife, Inc. completed the separation of Brighthouse Financial, Inc. and its subsidiaries (“Brighthouse”) through a distribution of 96,776,670 shares of Brighthouse Financial, Inc. common stock to the MetLife, Inc. common shareholders (the “Separation”). The results of Brighthouse are reflected in MetLife, Inc.’s interim condensed consolidated financial statements as discontinued operations and, therefore, are presented as income (loss) from discontinued operations on the consolidated statements of operations and comprehensive income (loss). Prior

year periods' results have been revised to reflect discontinued operations. Intercompany transactions between the Company and Brighthouse prior to the Separation have been eliminated. Transactions between the Company and Brighthouse after the Separation are reflected in continuing operations for the Company. See Note 3 for information on discontinued operations and transactions with Brighthouse.

7

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Reclassifications

Certain amounts in the prior year periods' interim condensed consolidated financial statements and related footnotes thereto have been reclassified to conform to the 2018 presentation as discussed throughout the Notes to the Interim Condensed Consolidated Financial Statements.

Revisions

As discussed in Note 1 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report, the Company made adjustments for group annuity reserves and assumed variable annuity guarantee reserves for which amounts previously reported have been immaterially restated. In addition, the Company has corrected other unrelated immaterial errors which were previously recorded in the periods the Company identified them.

A summary of the revisions to prior year periods' net income (loss) available to MetLife, Inc.'s common shareholders is shown in the table below:

	Three Months Ended June 30, 2017	Six Months Ended June 30, 2017
	(In millions)	
Assumed variable annuity guarantee reserves	\$47	\$ 61
Group annuity reserves	(9)	(18)
Other revisions to continuing operations, net	3	66
Impact to income (loss) from continuing operations before provision for income tax	41	109
Provision for income tax expense (benefit)	14	38
Impact to income (loss) from continuing operations, net of income tax	27	71
Other revisions to discontinued operations, net of income tax	—	3
Impact to net income (loss) available to MetLife, Inc.'s common shareholders	\$27	\$ 74

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

The impact of the revisions is shown in the tables below:

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	Three Months Ended June 30, 2017			Six Months Ended June 30,				
	As Previously Reported	Discontinued Operations	Revisions	As Revised	As Previously Reported	Discontinued Operations (1)	Revisions	As Revised
	(In millions, except per share data)							
Revenues								
Net investment gains (losses)	\$ 104	\$ —	\$ —	\$ 104	\$ 112	\$ 55	\$ 25	\$ 192
Net derivatives gains (losses)	\$(437)	\$ 190	\$ 47	\$(200)	\$(1,363)	\$ 890	\$ 61	\$(412)
Total revenues	\$ 17,245	\$(1,959)	\$ 47	\$ 15,333	\$ 33,514	\$(3,303)	\$ 86	\$ 30,297
Expenses								
Policyholder benefits and claims	\$ 10,302	\$(881)	\$ 6	\$ 9,427	\$ 20,161	\$(1,883)	\$ 12	\$ 18,290
Other expenses	\$ 4,059	\$(776)	\$ —	\$ 3,283	\$ 7,623	\$(1,037)	\$(35)	\$ 6,551
Total expenses	\$ 16,243	\$(1,934)	\$ 6	\$ 14,315	\$ 31,695	\$(3,465)	\$(23)	\$ 28,207
Income (loss) from continuing operations before provision for income tax	\$ 1,002	\$(25)	\$ 41	\$ 1,018	\$ 1,819	\$ 162	\$ 109	\$ 2,090
Provision for income tax expense (benefit)	\$ 115	\$ 33	\$ 14	\$ 162	\$ 103	\$ 141	\$ 38	\$ 282
Income (loss) from continuing operations, net of income tax	\$ 887	\$(58)	\$ 27	\$ 856	\$ 1,716	\$ 21	\$ 71	\$ 1,808
Income (loss) from discontinued operations, net of income tax	\$ —	\$ 58	\$ —	\$ 58	\$ —	\$(21)	\$ 3	\$(18)
Net income (loss)	\$ 887	\$ —	\$ 27	\$ 914	\$ 1,716	\$ —	\$ 74	\$ 1,790
Net income (loss) attributable to MetLife, Inc.	\$ 884	\$ —	\$ 27	\$ 911	\$ 1,710	\$ —	\$ 74	\$ 1,784
Net income (loss) available to MetLife, Inc.'s common shareholders	\$ 838	\$ —	\$ 27	\$ 865	\$ 1,658	\$ —	\$ 74	\$ 1,732
Comprehensive income (loss)	\$ 2,926	\$ —	\$ 27	\$ 2,953	\$ 4,805	\$ —	\$ 55	\$ 4,860
Comprehensive income (loss) attributable to MetLife, Inc.	\$ 2,924	\$ —	\$ 27	\$ 2,951	\$ 4,799	\$ —	\$ 55	\$ 4,854
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.'s common shareholders:								
Basic	\$ 0.78	\$(0.05)	\$ 0.03	\$ 0.76	\$ 1.53	\$ 0.02	\$ 0.07	\$ 1.62
Diluted	\$ 0.77	\$(0.05)	\$ 0.03	\$ 0.75	\$ 1.52	\$ 0.02	\$ 0.07	\$ 1.61

Net income (loss) available to
MetLife, Inc.'s common
shareholders per common
share:

Basic	\$0.78	\$ —	\$ 0.03	\$0.81	\$1.53	\$ —	\$ 0.07	\$1.60
Diluted	\$0.77	\$ —	\$ 0.03	\$0.80	\$1.52	\$ —	\$ 0.07	\$1.59

See Note 3 for additional information on discontinued operations. Revisions include \$5 million and \$2 million of (1) net investment gains (losses) and provision for income tax expense (benefit), respectively, related to discontinued operations.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Interim Condensed Consolidated Statements of Equity	As Previously Reported (In millions)	Revisions	As Revised
Retained Earnings			
Balance at December 31, 2016	\$34,480	\$ 203	\$34,683
Net income (loss)	\$1,710	\$ 74	\$1,784
Balance at June 30, 2017	\$35,270	\$ 277	\$35,547
Accumulated Other Comprehensive Income (Loss)			
Balance at December 31, 2016	\$5,347	\$ 19	\$5,366
Other comprehensive income (loss), net of income tax	\$3,089	\$ (19)	\$3,070
Balance at June 30, 2017	\$8,436	\$ —	\$8,436
Total MetLife, Inc.'s Stockholders' Equity			
Balance at December 31, 2016	\$67,309	\$ 222	\$67,531
Balance at June 30, 2017	\$69,455	\$ 277	\$69,732
Total Equity			
Balance at December 31, 2016	\$67,480	\$ 222	\$67,702
Balance at June 30, 2017	\$69,669	\$ 277	\$69,946

Adoption of New Accounting Pronouncements

Effective January 1, 2018, the Company early adopted guidance relating to income taxes. The new guidance was applied in the period of adoption. Current GAAP guidance requires that the effect of a change in tax laws or rates on deferred tax liabilities or assets to be included in income from continuing operations in the reporting period that includes the enactment date, even if the related income tax effects were originally charged or credited directly to accumulated other comprehensive income ("AOCI"). The Company's accounting policy for the release of stranded tax effects in AOCI is on an aggregate portfolio basis. The new guidance allows a reclassification of AOCI to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 ("U.S. Tax Reform"). Due to U.S. Tax Reform and the change in corporate tax rates, at December 22, 2017, the Company reported stranded tax effects in AOCI related to unrealized gains and losses on available-for-sale ("AFS") securities, cumulative foreign translation adjustments and deferred costs on pension benefit plans. With the adoption of the guidance, the Company released these stranded tax effects in AOCI resulting in a decrease to retained earnings as of January 1, 2018 of \$1.2 billion with a corresponding increase to AOCI.

Effective January 1, 2018, the Company prospectively adopted guidance relating to stock compensation. The new guidance includes guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Accounting Standards Codification ("ASC") Topic 718, Compensation - Stock Compensation. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

Effective January 1, 2018 the Company retrospectively adopted guidance on the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires that an employer that offers to its employees defined benefit pension or other postretirement benefit plans report the service cost component in the same line item or items as other compensation costs. The other components of net periodic benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. If a separate line item is not used, the line item used in the income statement to present the other components of net periodic benefit cost must be disclosed. In addition, the guidance allows only the service cost component to be eligible for capitalization when applicable. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

Effective January 1, 2018, the Company adopted, using a modified retrospective approach, guidance relating to de-recognition of nonfinancial assets. The new guidance clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” The new guidance also adds guidance for partial sales of nonfinancial assets. The adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Effective January 1, 2018, the Company retrospectively adopted guidance relating to restricted cash. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. As a result, the new guidance requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance does not provide a definition of restricted cash or restricted cash equivalents. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

Effective January 1, 2018, the Company adopted, using a modified retrospective approach, guidance relating to tax accounting for intra-entity transfers of assets. Prior guidance prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The new guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

Effective January 1, 2018, the Company retrospectively adopted guidance relating to cash flow statement presentation. The new guidance addresses diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

Effective January 1, 2018, the Company adopted, using a modified retrospective approach, guidance relating to recognition and measurement of financial instruments. The guidance changes the current accounting guidance related to (i) the classification and measurement of certain equity investments, (ii) the presentation of changes in the fair value of financial liabilities measured under the fair value option ("FVO") that are due to instrument-specific credit risk, and (iii) certain disclosures associated with the fair value of financial instruments. Effective January 1, 2018, there will no longer be a requirement to assess equity securities for impairment since such securities will be measured at fair value through net income. Additionally, there will no longer be a requirement to assess equity securities for embedded derivatives requiring bifurcation. The adoption of this guidance resulted in a \$328 million, net of income tax, increase to retained earnings largely offset by a decrease to AOCI that was primarily attributable to \$1.7 billion of equity securities previously classified and measured as equity securities AFS. At December 31, 2017, equity securities of \$16.0 billion primarily associated with contractholder-directed investments are accounted for using the FVO and therefore were unaffected by the new guidance. The Company has included the required disclosures related to equity securities within Note 6.

Effective January 1, 2018, the Company adopted, using a modified retrospective approach, guidance relating to revenue recognition. The new guidance supersedes nearly all existing revenue recognition guidance under U.S. GAAP. However, it does not impact the accounting for insurance and investment contracts within the scope of ASC Topic 944, Financial Services - Insurance, leases, financial instruments and certain guarantees. For those contracts that are impacted, the new guidance requires an entity to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled, in exchange for those goods or services. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.

For the three months and six months ended June 30, 2018, the Company identified \$328 million and \$650 million, respectively, of revenue streams within the scope of the guidance that are all included within other revenues on the interim condensed consolidated statements of operations and comprehensive income (loss). Such amounts primarily consisted of: (i) prepaid legal plans and administrative-only contracts within the U.S. segment of \$126 million and \$255 million, for the three months and six months ended June 30, 2018, respectively, (ii) distribution and administrative services fees within the MetLife Holdings segment of \$56 million and \$114 million for the three months and six months ended June 30, 2018, respectively, and (iii) fee-based investment management services within

Corporate & Other of \$74 million and \$145 million for the three months and six months ended June 30, 2018, respectively.

Substantially all of the revenue from these services is recognized over time as the applicable services are provided or are made available to the customers and control is transferred continuously. The consideration received for these services is variable and constrained to the amount not probable of a significant revenue reversal.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Other

Effective January 16, 2018, the London Clearing House (“LCH”) amended its rulebook, resulting in the characterization of variation margin transfers as settlement payments, as opposed to adjustments to collateral. These amendments impacted the accounting treatment of the Company’s centrally cleared derivatives, for which the LCH serves as the central clearing party. As of the effective date, the application of the amended rulebook reduced gross derivative assets by \$369 million, gross derivative liabilities by \$203 million, accrued investment income by \$14 million, collateral receivables recorded within premiums, reinsurance and other receivables by \$184 million, and collateral payables recorded within payables for collateral under securities loaned and other transactions by \$365 million. The application of the amended rulebook increased accrued investment expense recorded within other liabilities by \$1 million.

Future Adoption of New Accounting Pronouncements

In August 2017, the Financial Accounting Standards Board (“FASB”) issued new guidance on hedging activities (Accounting Standards Update (“ASU”) 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities). The new guidance is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years and should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. Early adoption is permitted. The new guidance simplifies the application of hedge accounting in certain situations and amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in their financial statements. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In March 2017, the FASB issued new guidance on purchased callable debt securities (ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities). The new guidance is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years and should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. Early adoption is permitted. The ASU shortens the amortization period for certain callable debt securities held at a premium and requires the premium to be amortized to the earliest call date. However, the new guidance does not require an accounting change for securities held at a discount whose discount continues to be amortized to maturity. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In January 2017, the FASB issued new guidance on goodwill impairment (ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment). The new guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The new guidance simplifies the current two-step goodwill impairment test by eliminating Step 2 of the test. See Note 11 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report for a description of the two-step test. The new guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, if any. The Company expects the adoption of this new guidance will reduce the complexity involved with the evaluation of goodwill for impairment. The impact of the new guidance will depend on the outcomes of future goodwill impairment tests.

In June 2016, the FASB issued new guidance on measurement of credit losses on financial instruments (ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments). The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This ASU replaces the incurred loss impairment methodology with one that reflects expected credit losses. The measurement of expected credit losses should be based on historical loss information, current conditions, and reasonable and supportable forecasts. The new guidance requires that an

other-than-temporary impairment (“OTTI”) on a debt security will be recognized as an allowance going forward, such that improvements in expected future cash flows after an impairment will no longer be reflected as a prospective yield adjustment through net investment income, but rather a reversal of the previous impairment and recognized through realized investment gains and losses. The guidance also requires enhanced disclosures. The Company has assessed the asset classes impacted by the new guidance and is currently assessing the accounting and reporting system changes that will be required to comply with the new guidance. The Company believes that the most significant impact upon adoption will be to its mortgage loan investments. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

In February 2016, the FASB issued new guidance on leasing transactions (ASU 2016-02, Leases - Topic 842). The new guidance is effective for the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and requires a modified retrospective transition approach (subject to optional practical expedients). Early adoption is permitted. The new guidance requires a lessee to recognize assets and liabilities for leases with lease terms of more than 12 months. Leases would be classified as finance or operating leases and both types of leases will be recognized on the balance sheet. Lessor accounting will remain largely unchanged from current guidance except for certain targeted changes. The new guidance will also require new qualitative and quantitative disclosures. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, amending certain aspects of the new leases standard. The amendments include clarification on whether to recognize a transition adjustment to earnings rather than through equity when an entity initially applies the new guidance retrospectively to each prior reporting period. Also, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements. The amendments in the new guidance provide entities with an additional transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Also, the amendments provide lessors with a practical expedient related to separating components of a contract. The Company's implementation efforts have been primarily focused on the review of its existing lease contracts, identification of other contracts that may fall under the scope of the new guidance, and performing a gap analysis on the current state of lease-related activities compared with the future state of lease-related activities. The Company identified its significant leases by geography and by asset type that will be impacted by the new guidance and has begun implementation of a new software platform to facilitate compliance with the new guidance. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

2. Segment Information

MetLife is organized into five segments: U.S.; Asia; Latin America; EMEA; and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other.

U.S.

The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into three businesses: Group Benefits, Retirement and Income Solutions and Property & Casualty.

The Group Benefits business offers insurance products and services which include life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision and accident & health coverages, as well as prepaid legal plans. This business also sells administrative services-only arrangements to some employers.

The Retirement and Income Solutions business offers a broad range of annuity and investment products, including stable value and pension risk transfer products, institutional income annuities, tort settlements, capital market investment products, as well as postretirement benefits and company-, bank- or trust-owned life insurance.

The Property & Casualty business offers personal and commercial lines of property and casualty insurance, including private passenger automobile, homeowners' and personal excess liability insurance. In addition, Property & Casualty offers small business owners property, liability and business interruption insurance.

Asia

The Asia segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include whole and term life, endowments, universal and variable life, accident & health insurance and fixed and variable annuities.

Latin America

The Latin America segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, retirement and savings products, accident &

health insurance and credit insurance.

13

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

EMEA

The EMEA segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident & health insurance, retirement and savings products and credit insurance.

MetLife Holdings

The MetLife Holdings segment consists of operations relating to products and businesses no longer actively marketed by the Company in the United States, such as variable, universal, term and whole life insurance, variable, fixed and index-linked annuities, long-term care insurance, as well as the assumed variable annuity guarantees from the Company's former operating joint venture in Japan.

Corporate & Other

Corporate & Other contains the excess capital, as well as certain charges and activities, not allocated to the segments, including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions, enterprise-wide strategic initiative restructuring charges and various start-up businesses (including the investment management business through which the Company offers fee-based investment management services to institutional clients). Additionally, Corporate & Other includes run-off businesses such as the direct to consumer portion of the U.S. Direct business. Corporate & Other also includes interest expense related to the majority of the Company's outstanding debt, as well as expenses associated with certain legal proceedings and income tax audit issues. In addition, Corporate & Other includes the elimination of intersegment amounts, which generally relate to affiliated reinsurance and intersegment loans, which bear interest rates commensurate with related borrowings.

Financial Measures and Segment Accounting Policies

Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company's GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for income (loss) from continuing operations, net of income tax. The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax.

The financial measures of adjusted revenues and adjusted expenses focus on the Company's primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP and other businesses that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP and are referred to as divested businesses. Divested businesses also includes the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Adjusted revenues also excludes net investment gains (losses) and net derivative gains (losses). Adjusted expenses also excludes goodwill impairments.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The following additional adjustments are made to revenues, in the line items indicated, in calculating adjusted revenues:

Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity guaranteed minimum income benefits (“GMIBs”) fees (“GMIB Fees”);

Net investment income: (i) includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed unit-linked investments, (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP and (v) includes distributions of profits from certain other limited partnership interests that were previously accounted for under the cost method, but are now accounted for at estimated fair value, where the change in estimated fair value is recognized in net investment gains (losses) for GAAP; and

Other revenues is adjusted for settlements of foreign currency earnings hedges and excludes fees received in association with services provided under transition service agreements (“TSA fees”).

The following additional adjustments are made to expenses, in the line items indicated, in calculating adjusted expenses:

Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”) and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);

Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;

Amortization of deferred policy acquisition costs (“DAC”) and value of business acquired (“VOBA”) excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs and (iii) Market Value Adjustments;

Amortization of negative VOBA excludes amounts related to Market Value Adjustments;

Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and

Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements and (iii) acquisition, integration and other costs. Other expenses includes TSA fees.

Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and six months ended June 30, 2018 and 2017. The segment accounting policies are the same as those used to prepare the Company’s consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below.

Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company's business.

15

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The Company's economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company's management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.

Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company's consolidated net investment income, income (loss) from continuing operations, net of income tax, or adjusted earnings.

Net investment income is based upon the actual results of each segment's specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company's product pricing.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Three Months Ended June 30, 2018	U.S.	Asia	Latin America	EMEA	MetLife Holdings	Corporate & Other	Total	Adjustments	Total Consolidated
	(In millions)								
Revenues									
Premiums	\$11,302	\$1,654	\$688	\$546	\$957	\$6	\$15,153	\$ —	\$15,153
Universal life and investment-type product policy fees	262	399	275	107	301	—	1,344	26	1,370
Net investment income	1,719	839	327	73	1,329	40	4,327	146	4,473
Other revenues	203	13	9	20	68	79	392	83	475
Net investment gains (losses)	—	—	—	—	—	—	—	(227)	(227)
Net derivative gains (losses)	—	—	—	—	—	—	—	(59)	(59)
Total revenues	13,486	2,905	1,299	746	2,655	125	21,216	(31)	21,185
Expenses									
Policyholder benefits and claims and policyholder dividends	11,233	1,237	660	286	1,706	3	15,125	50	15,175
Interest credited to policyholder account balances	439	362	95	26	235	—	1,157	267	1,424
Capitalization of DAC	(114)	(495)	(91)	(121)	(10)	(3)	(834)	—	(834)
Amortization of DAC and VOBA	114	313	71	108	101	1	708	(1)	707
Amortization of negative VOBA	—	(12)	—	(4)	—	—	(16)	—	(16)
Interest expense on debt	4	—	1	—	2	272	279	30	309
Other expenses	965	976	363	339	275	259	3,177	142	3,319
Total expenses	12,641	2,381	1,099	634	2,309	532	19,596	488	20,084
Provision for income tax expense (benefit)	174	161	55	26	66	(234)	248	(41)	207
Adjusted earnings	\$671	\$363	\$145	\$86	\$280	\$(173)	1,372		
Adjustments to:									
Total revenues							(31)		
Total expenses							(488)		
Provision for income tax (expense) benefit							41		
Income (loss) from continuing operations, net of income tax							\$894		\$894

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Three Months Ended June 30, 2017	U.S.	Asia	Latin America	EMEA	MetLife Holdings	Corporate & Other	Total	Adjustments	Total Consolidated
(In millions)									
Revenues									
Premiums	\$5,877	\$1,659	\$ 645	\$ 505	\$1,022	\$ 8	\$9,716	\$ (136)	\$ 9,580
Universal life and investment-type product policy fees	251	375	275	92	345	—	1,338	26	1,364
Net investment income	1,575	729	289	78	1,401	41	4,113	80	4,193
Other revenues	199	11	8	28	37	61	344	(52)	292
Net investment gains (losses)	—	—	—	—	—	—	—	104	104
Net derivative gains (losses)	—	—	—	—	—	—	—	(200)	(200)
Total revenues	7,902	2,774	1,217	703	2,805	110	15,511	(178)	15,333
Expenses									
Policyholder benefits and claims and policyholder dividends	5,887	1,247	596	270	1,717	1	9,718	22	9,740
Interest credited to policyholder account balances	359	333	94	25	255	—	1,066	226	1,292
Capitalization of DAC	(116)	(428)	(88)	(100)	(23)	(3)	(758)	14	(744)
Amortization of DAC and VOBA	114	290	68	95	139	1	707	(51)	656
Amortization of negative VOBA	—	(30)	—	(5)	—	—	(35)	(3)	(38)
Interest expense on debt	4	—	2	—	5	277	288	(4)	284
Other expenses	914	895	357	332	370	202	3,070	55	3,125
Total expenses	7,162	2,307	1,029	617	2,463	478	14,056	259	14,315
Provision for income tax expense (benefit)	247	157	34	14	105	(269)	288	(126)	162
Adjusted earnings	\$493	\$310	\$ 154	\$ 72	\$237	\$ (99)	1,167		
Adjustments to:									
Total revenues							(178)		
Total expenses							(259)		
Provision for income tax (expense) benefit							126		
Income (loss) from continuing operations, net of income tax							\$856		\$ 856

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Six Months Ended June 30, 2018	U.S.	Asia	Latin America	EMEA	MetLife Holdings	Corporate & Other	Total	Adjustments	Total Consolidated
	(In millions)								
Revenues									
Premiums	\$16,519	\$3,402	\$1,387	\$1,097	\$1,907	\$19	\$24,331	\$ —	\$24,331
Universal life and investment-type product policy fees	520	793	557	219	615	—	2,704	58	2,762
Net investment income	3,381	1,634	603	148	2,681	99	8,546	(328)	8,218
Other revenues	407	28	17	36	135	160	783	166	949
Net investment gains (losses)	—	—	—	—	—	—	—	(560)	(560)
Net derivative gains (losses)	—	—	—	—	—	—	—	290	290
Total revenues	20,827	5,857	2,564	1,500	5,338	278	36,364	(374)	35,990
Expenses									
Policyholder benefits and claims and policyholder dividends	16,371	2,580	1,306	580	3,256	—	24,093	97	24,190
Interest credited to policyholder account balances	846	713	193	51	471	—	2,274	(81)	2,193
Capitalization of DAC	(220)	(960)	(185)	(239)	(20)	(5)	(1,629)	(1)	(1,630)
Amortization of DAC and VOBA	229	627	131	214	201	3	1,405	(5)	1,400
Amortization of negative VOBA	—	(27)	—	(10)	—	—	(37)	(1)	(38)
Interest expense on debt	6	—	3	—	4	552	565	30	595
Other expenses	1,926	1,928	701	690	551	491	6,287	236	6,523
Total expenses	19,158	4,861	2,149	1,286	4,463	1,041	32,958	275	33,233
Provision for income tax expense (benefit)	345	306	130	47	170	(393)	605	1	606
Adjusted earnings	\$1,324	\$690	\$285	\$167	\$705	\$(370)	2,801		
Adjustments to:									
Total revenues							(374)		
Total expenses							(275)		
Provision for income tax (expense) benefit							(1)		
Income (loss) from continuing operations, net of income tax							\$2,151		\$2,151

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Six Months Ended June 30, 2017	U.S.	Asia	Latin America	EMEA	MetLife Holdings	Corporate & Other	Total	Adjustments	Total Consolidated
(In millions)									
Revenues									
Premiums	\$11,062	\$3,367	\$1,292	\$1,007	\$2,081	\$46	\$18,855	\$(310)	\$18,545
Universal life and investment-type product policy fees	516	741	535	187	707	—	2,686	38	2,724
Net investment income	3,187	1,431	592	152	2,842	81	8,285	329	8,614
Other revenues	403	21	17	45	133	120	739	(105)	634
Net investment gains (losses)	—	—	—	—	—	—	—	192	192
Net derivative gains (losses)	—	—	—	—	—	—	—	(412)	(412)
Total revenues	15,168	5,560	2,436	1,391	5,763	247	30,565	(268)	30,297
Expenses									
Policyholder benefits and claims and policyholder dividends	11,131	2,562	1,229	539	3,450	26	18,937	(24)	18,913
Interest credited to policyholder account balances	710	654	176	49	512	1	2,102	641	2,743
Capitalization of DAC	(216)	(848)	(170)	(192)	(57)	(4)	(1,487)	30	(1,457)
Amortization of DAC and VOBA	228	581	146	182	213	2	1,352	(33)	1,319
Amortization of negative VOBA	—	(67)	—	(8)	—	—	(75)	(6)	(81)
Interest expense on debt	6	—	3	—	20	554	583	(16)	567
Other expenses	1,823	1,770	683	648	710	377	6,011	192	6,203
Total expenses	13,682	4,652	2,067	1,218	4,848	956	27,423	784	28,207
Provision for income tax expense (benefit)	496	303	72	26	291	(540)	648	(366)	282
Adjusted earnings	\$990	\$605	\$297	\$147	\$624	\$(169)	2,494		
Adjustments to:									
Total revenues							(268)		
Total expenses							(784)		
Provision for income tax (expense) benefit							366		
Income (loss) from continuing operations, net of income tax							\$1,808		\$1,808

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The following table presents total assets with respect to the Company's segments, as well as Corporate & Other, at:

	June 30, 2018	December 31, 2017
	(In millions)	
U.S.	\$256,668	\$ 255,428
Asia	141,653	136,928
Latin America	73,214	79,670
EMEA	29,353	30,500
MetLife Holdings	174,470	183,160
Corporate & Other	30,975	34,206
Total	\$706,333	\$ 719,892

Revenues derived from one U.S. segment customer were \$6.0 billion for both the three months and six months ended June 30, 2018, which represented 35% and 21%, respectively, of consolidated premiums, universal life and investment-type product policy fees and other revenues. The revenue was from a single premium received for a pension risk transfer. Revenues derived from any other customer did not exceed 10% of consolidated premiums, universal life and investment-type product policy fees and other revenues for the three months and six months ended June 30, 2018 and 2017.

3. Dispositions

2018 Disposition

On February 20, 2018, the Company completed the sale of MetLife Afore, S.A. de C.V., its pension fund management business in Mexico. See Note 3 of the Notes to the Consolidated Financial Statement included in the 2017 Annual Report for further information.

2017 Separation of Brighthouse

On August 4, 2017, MetLife, Inc. completed the separation of Brighthouse. MetLife, Inc. retained the remaining ownership interest of 22,996,436 shares, or 19.2%, of Brighthouse Financial, Inc. common stock and recognized its investment in Brighthouse Financial, Inc. common stock based on the NASDAQ reported market price. The Company elected to record the investment under the FVO as an observable measure of estimated fair value that is aligned with the Company's intent to divest of the retained shares as soon as practicable. Subsequent changes in estimated fair value of the investment were recorded to net investment gains (losses). The estimated fair value of the Brighthouse Financial, Inc. common stock held by the Company ("FVO Brighthouse Common Stock") at December 31, 2017 was \$1.3 billion reported within contractholder-directed equity securities and fair value option securities ("FVO Securities") (collectively, "Unit-linked and FVO Securities").

The Company incurred pre-tax Separation-related transaction costs of \$330 million and \$407 million for the three months and six months ended June 30, 2017, respectively, primarily related to the terminations of financing agreements and third party staffing costs. For both the three months and six months ended June 30, 2017, the Company reported \$294 million within discontinued operations for fees for the terminations of financing arrangements. All other Separation-related transaction costs are recorded in other expenses and reported within continuing operations.

In June 2018, the Company sold FVO Brighthouse Common Stock in exchange for \$944 million aggregate principal amount of MetLife, Inc. senior notes, which MetLife, Inc. canceled. The Company recorded \$159 million and \$327 million of mark-to-market and disposition losses on the FVO Brighthouse Common Stock to net investment gains (losses) for the three months and six months ended June 30, 2018, respectively. As of June 30, 2018, the Company no longer held any shares of Brighthouse Financial, Inc. for its own account; however, certain insurance company separate accounts managed by the Company held shares of Brighthouse Financial, Inc. See Note 9 for further information on this transaction.

See Note 3 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report for further information regarding the Separation, including Separation-related agreements and ongoing transactions with Brighthouse.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

Agreements

Tax Agreements

Immediately prior to the Separation, MetLife entered into tax agreements with Brighthouse.

In accordance with the tax separation agreement, at both June 30, 2018 and December 31, 2017, the Company's current income tax receivable and corresponding payable to Brighthouse, reported in other liabilities, were \$726 million.

As part of the tax receivable agreement, MetLife Inc. has the right to receive future payments from Brighthouse for a tax asset that Brighthouse received as a result of restructuring prior to the Separation. Included in other assets at both June 30, 2018 and December 31, 2017, is a receivable from Brighthouse of \$333 million related to these future payments.

Ongoing Transactions with Brighthouse

The Company considered all of its continuing involvement with Brighthouse in determining whether to deconsolidate and present Brighthouse results as discontinued operations, including the agreements entered into between MetLife and Brighthouse and the ongoing transactions described below.

The Company entered into reinsurance, committed facility, structured settlement, and contract administrative services transactions with Brighthouse in the normal course of business and such transactions will continue based upon business needs. In addition, prior to and in connection with the Separation, the Company entered into various other agreements with Brighthouse for services necessary for both the Company and Brighthouse to conduct their activities. Intercompany transactions prior to the Separation between the Company and Brighthouse are eliminated and excluded from the interim condensed consolidated statements of operations and comprehensive income (loss). Transactions between the Company and Brighthouse that continue after the Separation are included on the Company's interim condensed consolidated statements of operations and comprehensive income (loss) and interim condensed consolidated balance sheets.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

Reinsurance

The Company entered into reinsurance transactions with Brighthouse in the normal course of business and such transactions will continue based upon business needs. Information regarding the significant effects of reinsurance transactions with Brighthouse was as follows:

	Included on Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Three Months Ended June 30, 2018 2017 (In millions)		Included on Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Six Months Ended June 30, 2018 2017	
Premiums				
Reinsurance assumed	\$105	\$ 115	\$ 201	\$ 212
Reinsurance ceded	(3)	(4)	(6)	(7)
Net premiums	\$102	\$ 111	\$ 195	\$ 205
Universal life and investment-type product policy fees				
Reinsurance assumed	\$(3)	\$(1)	\$(2)	\$(5)
Reinsurance ceded	(20)	(22)	(44)	(46)
Net universal life and investment-type product policy fees	\$(23)	\$(23)	\$(46)	\$(51)
Policyholder benefits and claims				
Reinsurance assumed	\$84	\$ 91	\$ 162	\$ 166
Reinsurance ceded	—	(6)	(10)	(12)
Net policyholder benefits and claims	\$84	\$ 85	\$ 152	\$ 154
Interest credited to policyholder account balances				
Reinsurance assumed	\$3	\$ 4	\$ 7	\$ 8
Reinsurance ceded	(17)	(18)	(35)	(36)
Net interest credited to policyholder account balances	\$(14)	\$(14)	\$(28)	\$(28)
Other expenses				
Reinsurance assumed	\$31	\$ 36	\$ 65	\$ 6
Reinsurance ceded	(4)	(4)	(18)	(25)
Net other expenses	\$27	\$ 32	\$ 47	\$ (19)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

Information regarding the significant effects of reinsurance transactions with Brighthouse included on the interim condensed consolidated balance sheets was as follows at:

	June 30, 2018		December 31, 2017	
	Assumed	Ceded	Assumed	Ceded
	(In millions)			
Assets				
Premiums, reinsurance and other receivables	\$ 157	\$ 1,788	\$ 167	\$ 1,793
Deferred policy acquisition costs and value of business acquired	381	(40)	384	(40)
Total assets	\$ 538	\$ 1,748	\$ 551	\$ 1,753
Liabilities				
Future policy benefits	\$ 1,842	\$ —	\$ 1,734	\$ —
Other policy-related balances	120	22	119	28
Other liabilities	1,446	16	1,458	19
Total liabilities	\$ 3,408	\$ 38	\$ 3,311	\$ 47

Investment Management

In connection with the Separation, the Company entered into investment management services agreements with Brighthouse. During the three months and six months ended June 30, 2018, the Company recognized \$32 million and \$61 million, respectively, in other revenues for services provided under such investment management services agreements. Prior to the Separation, during the three months and six months ended June 30, 2017, the Company charged Brighthouse \$24 million and \$49 million, respectively, for services provided under the agreements, which were intercompany transactions and eliminated and excluded from the interim condensed consolidated statements of operations and comprehensive income (loss).

Committed Facility

MetLife Reinsurance Company of Vermont and MetLife, Inc. have a \$2.9 billion committed facility which is used as collateral for certain affiliated reinsurance liabilities. At June 30, 2018, Brighthouse was a beneficiary of \$2.4 billion of letters of credit issued under this committed facility and, in consideration, Brighthouse reimbursed MetLife, Inc. for a portion of the letter of credit fees. Prior to the Separation, the Company entered into the committed facility with Brighthouse in the normal course of business and such transactions will continue based upon business needs.

Transition Services

In connection with the Separation, the Company entered into a transition services agreement with Brighthouse for services necessary for Brighthouse to conduct its activities. During the three months and six months ended June 30, 2018, the Company recognized \$78 million and \$157 million, respectively, as other revenue for transitional services provided under the agreement. Prior to the Separation, during the three months and six months ended June 30, 2017, the Company charged Brighthouse \$83 million and \$164 million, respectively, for services provided under the agreement, which were intercompany transactions and eliminated and excluded from the interim condensed consolidated statements of operations and comprehensive income (loss).

Other

The Company has existing assumed structured settlement claim obligations as an assignment company for Brighthouse. These liabilities are measured at the present value of the periodic claims to be provided and reported as other policy-related balances. The Company receives a fee for assuming these claim obligations and, as the assignee of the claim, is legally obligated to ensure periodic payments are made to the claimant. The Company purchased annuities from Brighthouse to fund these obligations and designates payments to be made directly to the claimant by Brighthouse as the annuity writer. The aggregate contract values of annuities funding structured settlement claims are recorded as an asset for which the Company has also recorded an unpaid claim obligation reported in other

policy-related balances. Such aggregated contract values were \$1.3 billion at both June 30, 2018 and December 31, 2017. The Company entered into these transactions with Brighthouse in the normal course of business and such transactions will continue based upon business needs.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

The Company provides services necessary for Brighthouse to conduct its business, which primarily include contract administrative services for certain Brighthouse investment-type products. During the three months and six months ended June 30, 2018, the Company recognized revenue of \$31 million and \$63 million, respectively, for administrative services provided to Brighthouse. Prior to the Separation, during the three months and six months ended June 30, 2017, the Company provided administrative services to Brighthouse for \$31 million and \$62 million, respectively, which were intercompany transactions and eliminated and excluded from the interim condensed consolidated statements of operations and comprehensive income (loss). The Company entered into these transactions with Brighthouse in the normal course of business and such transactions will continue based upon business needs. In connection with the Separation, the Company entered into an employee matters agreement with Brighthouse to allocate obligations and responsibilities relating to employee compensation and benefit plans and other related matters. The employee matters agreement provides that MetLife will reimburse Brighthouse for certain pension benefit payments, retiree health and life benefit payments and deferred compensation payments. Included in other liabilities at June 30, 2018 and December 31, 2017, are payables to Brighthouse of \$179 million and \$186 million, respectively, related to these future payments.

At June 30, 2018 and December 31, 2017, the Company had receivables from Brighthouse of \$111 million and \$97 million, respectively, related to services provided.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

Discontinued Operations

The following table presents the amounts related to the operations of Brighthouse that have been reflected in discontinued operations:

	Three Months Ended June 30, 2017	Six Months Ended June 30, 2017
	(In millions)	
Revenues		
Premiums	\$355	\$ 705
Universal life and investment-type product policy fees	938	1,880
Net investment income	766	1,541
Other revenues	90	122
Total net investment gains (losses)	—	(50)
Net derivative gains (losses)	(190)	(890)
Total revenues	1,959	3,308
Expenses		
Policyholder benefits and claims	881	1,883
Interest credited to policyholder account balances	270	531
Policyholder dividends	7	14
Other expenses	776	1,037
Total expenses	1,934	3,465
Income (loss) from discontinued operations before provision for income tax	25	(157)
Provision for income tax expense (benefit)	(33)	(139)
Income (loss) from discontinued operations, net of income tax	\$58	\$ (18)

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

In the interim condensed consolidated statements of cash flows, the cash flows from discontinued operations are not separately classified. The following table presents selected financial information regarding cash flows of the discontinued operations.

	Six Months Ended June 30, 2017 (In millions)
Net cash provided by (used in):	
Operating activities	\$ 1,310
Investing activities	\$(2,288)
Financing activities	\$ 195

4. Insurance

Guarantees

As discussed in Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report, the Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. Guaranteed minimum accumulation benefits (“GMABs”) and the portions of both non-life-contingent guaranteed minimum withdrawal benefits (“GMWBs”) and the GMIBs that do not require annuitization are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 7.

The Company also issues other annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash and a higher rate if the contractholder elects to annuitize. These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit.

Information regarding the Company’s guarantee exposure, which includes direct and assumed business, but excludes offsets from hedging or ceded reinsurance, if any, was as follows at:

	June 30, 2018		December 31, 2017	
	In the Event of Death	At Annuitization	In the Event of Death	At Annuitization
	(Dollars in millions)			
Annuity Contracts:				
Variable Annuity Guarantees:				
Total account value (1), (2), (3)	\$63,195	\$ 24,673	\$66,724	\$ 26,223
Separate account value (1)	\$42,991	\$ 22,802	\$45,431	\$ 24,336
Net amount at risk (2)	\$1,599 (4)	\$ 510 (5)	\$1,238 (4)	\$ 525 (5)
Average attained age of contractholders	66 years	66 years	65 years	65 years
Other Annuity Guarantees:				
Total account value (1), (3)	N/A	\$ 1,330	N/A	\$ 1,424
Net amount at risk	N/A	\$ 517 (6)	N/A	\$ 569 (6)
Average attained age of contractholders	N/A	50 years	N/A	50 years

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Insurance (continued)

	June 30, 2018		December 31, 2017	
	Secondary	Paid-Up	Secondary	Paid-Up
	Guarantees	Guarantees	Guarantees	Guarantees
	(Dollars in millions)			
Universal and Variable Life Contracts:				
Total account value (1), (3)	\$9,089	\$ 3,136	\$9,036	\$ 3,207
Net amount at risk (7)	\$65,541	\$ 16,060	\$66,956	\$ 16,615
Average attained age of policyholders	57 years	64 years	56 years	63 years

- (1) The Company's annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive.
- (2) Includes amounts, which are not reported on the interim condensed consolidated balance sheets, from assumed variable annuity guarantees from the Company's former operating joint venture in Japan.
- (3) Includes the contractholder's investments in the general account and separate account, if applicable.
Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and
- (4) includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death.
Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company's potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved.
- (5) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a
- (6) lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company's potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date.
- (7) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Insurance (continued)

Liabilities for Unpaid Claims and Claim Expenses

Rollforward of Claims and Claim Adjustment Expenses

Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:

	Six Months Ended June 30,	
	2018	2017 (1)
	(In millions)	
Balance, beginning of period	\$17,094	\$16,157
Less: Reinsurance recoverables	2,198	1,968
Net balance, beginning of period	14,896	14,189
Incurred related to:		
Current period	12,257	12,747
Prior periods (2)	200	24
Total incurred	12,457	12,771
Paid related to:		
Current period	(8,021)	(8,709)
Prior periods	(4,146)	(3,753)
Total paid	(12,167)	(12,462)
Net balance, end of period	15,186	14,498
Add: Reinsurance recoverables	2,289	2,227
Balance, end of period (included in future policy benefits and other policy-related balances)	\$17,475	\$16,725

As discussed in Note 4 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report, at December 31, 2016, the Net balance decreased and the Reinsurance recoverables increased from those amounts previously reported. Additionally, at June 30, 2017, the Net balance decreased by \$150 million and the (1) Reinsurance recoverables increased by \$147 million from those amounts previously reported in MetLife, Inc.'s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017. These adjustments to the Net balance and the Reinsurance recoverables, at both periods, are primarily to correct for improper classification of reinsurance recoverables.

During both the six months ended June 30, 2018 and 2017, as a result of changes in estimates of insured events in (2) the respective prior periods, the claims and claim adjustment expenses associated with prior periods increased due to unfavorable claims experience.

5. Closed Block

On April 7, 2000 (the "Demutualization Date"), Metropolitan Life Insurance Company ("MLIC") converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC's plan of reorganization, as amended (the "Plan of Reorganization"). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC.

Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company's net income continues to be sensitive to the actual performance of the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Closed Block (continued)

Information regarding the closed block liabilities and assets designated to the closed block was as follows at:

	June 30, 2018	December 31, 2017
	(In millions)	
Closed Block Liabilities		
Future policy benefits	\$40,180	\$ 40,463
Other policy-related balances	204	222
Policyholder dividends payable	468	437
Policyholder dividend obligation	792	2,121
Other liabilities	371	212
Total closed block liabilities	42,015	43,455
Assets Designated to the Closed Block		
Investments:		
Fixed maturity securities available-for-sale, at estimated fair value	26,194	27,904
Equity securities, at estimated fair value	68	70
Mortgage loans	6,290	5,878
Policy loans	4,520	4,548
Real estate and real estate joint ventures	591	613
Other invested assets	694	731
Total investments	38,357	39,744
Accrued investment income	457	477
Premiums, reinsurance and other receivables; cash and cash equivalents	70	14
Current income tax recoverable	36	35
Deferred income tax assets	19	36
Total assets designated to the closed block	38,939	40,306
Excess of closed block liabilities over assets designated to the closed block	3,076	3,149
Amounts included in AOCI:		
Unrealized investment gains (losses), net of income tax	1,312	1,863
Unrealized gains (losses) on derivatives, net of income tax	16	(7)
Allocated to policyholder dividend obligation, net of income tax	(626)	(1,379)
Total amounts included in AOCI	702	477
Maximum future earnings to be recognized from closed block assets and liabilities	\$3,778	\$ 3,626

See Note 1 for discussion of new accounting guidance related to U.S. Tax Reform.

Information regarding the closed block policyholder dividend obligation was as follows:

	Six Months Ended June 30, 2018	Year Ended December 31, 2017
	(In millions)	
Balance, beginning of period	\$2,121	\$ 1,931
Change in unrealized investment and derivative gains (losses)	(1,329)	190
Balance, end of period	\$792	\$ 2,121

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Closed Block (continued)

Information regarding the closed block revenues and expenses was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
	(In millions)			
Revenues				
Premiums	\$410	\$432	\$797	\$834
Net investment income	431	452	875	918
Net investment gains (losses)	(24)	(2)	(53)	(10)
Net derivative gains (losses)	13	(10)	10	(18)
Total revenues	830	872	1,629	1,724
Expenses				
Policyholder benefits and claims	596	614	1,167	1,182
Policyholder dividends	238	247	482	497
Other expenses	30	32	59	64
Total expenses	864	893	1,708	1,743
Revenues, net of expenses before provision for income tax expense (benefit)	(34)	(21)	(79)	(19)
Provision for income tax expense (benefit)	(7)	(8)	(17)	(8)
Revenues, net of expenses and provision for income tax expense (benefit)	\$(27)	\$(13)	\$(62)	\$(11)

MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments

Fixed Maturity Securities Available-for-Sale

Fixed Maturity Securities Available-for-Sale by Sector

The following table presents the fixed maturity securities AFS by sector. Redeemable preferred stock is reported within U.S. corporate and foreign corporate fixed maturity securities. Included within fixed maturity securities AFS are structured securities including residential mortgage-backed securities (“RMBS”), asset-backed securities (“ABS”) and commercial mortgage-backed securities (“CMBS”) (collectively, “Structured Securities”).

	June 30, 2018				December 31, 2017					
	Amortized Cost	Gross Unrealized Gains	Temporary Losses	OTTI Losses (1)	Estimated Fair Value	Amortized Cost	Gross Unrealized Gains	Temporary Losses	OTTI Losses (1)	Estimated Fair Value
(In millions)										
Fixed maturity securities:										
U.S. corporate	\$81,382	\$4,233	\$ 1,589	\$—	\$84,026	\$76,005	\$7,007	\$ 351	\$—	\$82,661
Foreign government	56,106	6,082	506	—	61,682	55,351	6,495	312	—	61,534
Foreign corporate	52,930	2,780	1,433	—	54,277	52,409	3,836	676	—	55,569
U.S. government and agency	42,701	3,229	543	—	45,387	43,446	4,227	279	—	47,394
RMBS	27,390	976	556	(35)	27,845	27,846	1,145	233	(42)	28,800
State and political subdivision	10,683	1,395	52	—	12,026	10,752	1,717	13	1	12,455
ABS	12,818	85	36	1	12,866	12,213	116	39	(1)	12,291
CMBS	8,247	92	117	—	8,222	8,047	222	42	—	8,227
Total fixed maturity securities	\$292,257	\$18,872	\$ 4,832	\$(34)	\$306,331	\$286,069	\$24,765	\$ 1,945	\$(42)	\$308,931

Noncredit OTTI losses included in AOCI in an unrealized gain position are due to increases in estimated fair value (1) subsequent to initial recognition of noncredit losses on such securities. See also “— Net Unrealized Investment Gains (Losses).”

The Company held non-income producing fixed maturity securities with an estimated fair value of \$24 million and \$6 million, and unrealized gains (losses) of (\$1) million and (\$4) million, at June 30, 2018 and December 31, 2017, respectively.

Maturities of Fixed Maturity Securities

The amortized cost and estimated fair value of fixed maturity securities, by contractual maturity date, were as follows at June 30, 2018:

	Due in One Year or Less	Due After One Year Through Five Years	Due After Five Years	Due After Ten Years	Structured Securities	Total Fixed Maturity Securities
(In millions)						
Amortized cost	\$13,437	\$59,285	\$61,369	\$109,711	\$ 48,455	\$292,257
Estimated fair value	\$13,456	\$60,971	\$63,077	\$119,894	\$ 48,933	\$306,331

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities not due at a single maturity date have been presented in the year of final contractual maturity. Structured Securities are shown separately, as they are not due at a single maturity.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position, aggregated by sector and by length of time that the securities have been in a continuous unrealized loss position at:

	June 30, 2018				December 31, 2017			
	Less than 12 Months		Equal to or Greater than 12 Months		Less than 12 Months		Equal to or Greater than 12 Months	
	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses
	(Dollars in millions)							
Fixed maturity securities:								
U.S. corporate	\$29,888	\$ 1,145	\$4,227	\$ 444	\$5,604	\$ 92	\$4,115	\$ 259
Foreign government	5,007	258	2,960	248	4,234	83	3,251	229
Foreign corporate	14,309	865	4,676	568	4,422	99	6,802	577
U.S. government and agency	18,165	217	3,300	326	18,273	93	3,560	186
RMBS	11,604	307	3,537	214	6,359	50	4,159	141
State and political subdivision	1,064	31	299	21	182	2	346	12
ABS	4,588	17	445	20	1,695	7	729	31
CMBS	4,276	74	421	43	1,174	9	413	33
Total fixed maturity securities	\$88,901	\$ 2,914	\$19,865	\$ 1,884	\$41,943	\$ 435	\$23,375	\$ 1,468
Total number of securities in an unrealized loss position	6,572		1,881		2,598		1,955	

Evaluation of AFS Securities for OTTI and Evaluating Temporarily Impaired AFS Securities

As described more fully in Notes 1 and 8 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report, the Company performs a regular evaluation of all investment classes for impairment, including fixed maturity securities and perpetual hybrid securities, in accordance with its impairment policy, in order to evaluate whether such investments are other-than-temporarily impaired.

Current Period Evaluation

Based on the Company's current evaluation of its AFS securities in an unrealized loss position in accordance with its impairment policy, and the Company's current intentions and assessments (as applicable to the type of security) about holding, selling and any requirements to sell these securities, the Company concluded that these securities were not other-than-temporarily impaired at June 30, 2018. Future OTTI will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings, collateral valuation, interest rates and credit spreads. If economic fundamentals deteriorate or if there are adverse changes in the above factors, OTTI may be incurred in upcoming periods.

Gross unrealized losses on fixed maturity securities increased \$2.9 billion during the six months ended June 30, 2018 to \$4.8 billion. The increase in gross unrealized losses for the six months ended June 30, 2018 was primarily attributable to widening credit spreads, increases in interest rates and to a lesser extent, the impact of weakening foreign currencies on non-functional currency denominated fixed maturity securities.

At June 30, 2018, \$67 million of the total \$4.8 billion of gross unrealized losses were from 32 fixed maturity securities with an unrealized loss position of 20% or more of amortized cost for six months or greater.

Investment Grade Fixed Maturity Securities

Of the \$67 million of gross unrealized losses on fixed maturity securities with an unrealized loss of 20% or more of amortized cost for six months or greater, \$15 million, or 22%, were related to gross unrealized losses on 10 investment grade fixed maturity securities. Unrealized losses on investment grade fixed maturity securities are

principally related to widening credit spreads since purchase and, with respect to fixed-rate fixed maturity securities, rising interest rates since purchase.

33

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Below Investment Grade Fixed Maturity Securities

Of the \$67 million of gross unrealized losses on fixed maturity securities with an unrealized loss of 20% or more of amortized cost for six months or greater, \$52 million, or 78%, were related to gross unrealized losses on 22 below investment grade fixed maturity securities. Unrealized losses on below investment grade fixed maturity securities are principally related to U.S. and foreign corporate securities (primarily industrial and utility securities) and CMBS and are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty. Management evaluates U.S. and foreign corporate securities based on factors such as expected cash flows and the financial condition and near-term and long-term prospects of the issuers and evaluates CMBS based on actual and projected cash flows after considering the quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, the payment terms of the underlying assets backing a particular security and the payment priority within the tranche structure of the security.

Equity Securities

Equity securities are summarized as follows at:

	June 30, 2018		December 31, 2017	
	Estimated Fair Value	% of Total	Estimated Fair Value	% of Total
(Dollars in millions)				
Equity securities:				
Common stock	\$1,062	71.6 %	\$2,035	81.0 %
Non-redeemable preferred stock	421	28.4	478	19.0
Total equity securities	\$1,483	100.0%	\$2,513	100.0%

In connection with the adoption of new guidance related to the recognition and measurement of financial instruments (see Note 1), effective January 1, 2018, the Company has reclassified its investment in common stock in regional banks of the Federal Home Loan Bank (“FHLB”) system from equity securities to other invested assets. These investments are carried at redemption value and are considered restricted investments until redeemed by the respective FHLB regional banks. The carrying value of these investments at December 31, 2017 was \$791 million.

Unit-linked and FVO Securities

Unit-linked and FVO Securities are investments for which the FVO has been elected, or are otherwise required to be carried at estimated fair value, and include:

contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”) which do not qualify for presentation and reporting as separate account summary total assets and liabilities. These investments are primarily equity securities (including mutual funds) and, to a lesser extent, fixed maturity securities, short-term investments and cash and cash equivalents. The investment returns on these investments inure to contractholders and are offset by a corresponding change in policyholder account balances through interest credited to policyholder account balances;

fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products and investments in certain separate accounts; and securities held by consolidated securitization entities.

At December 31, 2017, Unit-linked and FVO Securities also included FVO Brighthouse Common Stock (see Note 3).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Mortgage Loans

Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:

	June 30, 2018		December 31, 2017	
	Carrying Value	% of Total	Carrying Value	% of Total
	(Dollars in millions)			
Mortgage loans:				
Commercial	\$46,075	65.0 %	\$44,375	64.6 %
Agricultural	13,293	18.8	13,014	18.9
Residential	11,404	16.1	11,136	16.2
Subtotal (1)	70,772	99.9	68,525	99.7
Valuation allowances	(325)	(0.5)	(314)	(0.5)
Subtotal mortgage loans, net	70,447	99.4	68,211	99.2
Residential — FVO	405	0.6	520	0.8
Total mortgage loans, net	\$70,852	100.0 %	\$68,731	100.0 %

Purchases of mortgage loans, primarily residential mortgage loans, were \$666 million and \$973 million for the (1) three months and six months ended June 30, 2018, respectively, and \$742 million and \$1.5 billion for the three months and six months ended June 30, 2017, respectively.

Information on commercial, agricultural and residential mortgage loans is presented in the tables below. Information on residential mortgage loans — FVO is presented in Note 8. The Company elects the FVO for certain residential mortgage loans that are managed on a total return basis.

The carrying value of foreclosed mortgage loans included in real estate and real estate joint ventures was \$45 million and \$48 million at June 30, 2018 and December 31, 2017, respectively.

Mortgage Loans, Valuation Allowance and Impaired Loans by Portfolio Segment

Mortgage loans by portfolio segment, by method of evaluation of credit loss, impaired mortgage loans including those modified in a troubled debt restructuring, and the related valuation allowances, were as follows at:

	Evaluated Individually for Credit Losses			Evaluated Collectively for Credit Losses		Impaired Loans
	Impaired Loans with a Valuation Allowance			Impaired Loans without a Valuation Allowance		Carrying Value
	Unpaid Principal Balance	Recorded Investment	Valuation Allowances	Unpaid Principal Balance	Recorded Investment	Recorded Valuation Allowances
	(In millions)					
June 30, 2018						
Commercial	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 227
Agricultural	13	13	2	112	111	39
Residential	—	—	—	401	362	57
Total	\$13	\$13	\$2	\$513	\$473	\$323
December 31, 2017						
Commercial	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Agricultural	13	13	2	112	111	39
Residential	—	—	—	401	362	57
Total	\$13	\$13	\$2	\$513	\$473	\$323

Edgar Filing: METLIFE INC - Form 10-Q

Commercial	\$—	\$ —	\$ —	\$ —	\$ —	\$44,375	\$ 214	\$ —
Agricultural	22	21	2	27	27	12,966	39	46
Residential	—	—	—	358	324	10,812	59	324
Total	\$22	\$ 21	\$ 2	\$385	\$ 351	\$68,153	\$ 312	\$ 370

35

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The average recorded investment for impaired commercial, agricultural and residential mortgage loans was \$0, \$122 million and \$351 million, respectively, for the three months ended June 30, 2018; and \$0, \$97 million and \$342 million, respectively, for the six months ended June 30, 2018;

The average recorded investment for impaired commercial, agricultural and residential mortgage loans was \$6 million, \$13 million and \$278 million, respectively, for the three months ended June 30, 2017; and \$8 million, \$21 million and \$266 million, respectively, for the six months ended June 30, 2017.

Valuation Allowance Rollforward by Portfolio Segment

The changes in the valuation allowance, by portfolio segment, were as follows:

	Six Months Ended June 30, 2018				2017			
	Commercial	Agricultural	Residential	Total	Commercial	Agricultural	Residential	Total
Balance, beginning of period	\$ 214	\$ 41	\$ 59	\$ 314	\$ 202	\$ 39	\$ 63	\$ 304
Provision (release)	13	—	2	15	6	—	9	15
Charge-offs, net of recoveries	—	—	(4)	(4)	—	—	(7)	(7)
Balance, end of period	\$ 227	\$ 41	\$ 57	\$ 325	\$ 208	\$ 39	\$ 65	\$ 312

Credit Quality of Commercial Mortgage Loans

The credit quality of commercial mortgage loans was as follows at:

	Recorded Investment Debt Service Coverage Ratios				% of Total	Estimated Fair Value	% of Total
	> 1.20x	1.00x - 1.20x	< 1.00x	Total			
(Dollars in millions)							
June 30, 2018							
Loan-to-value ratios:							
Less than 65%	\$39,229	\$ 691	\$ 202	\$40,122	87.1 %	\$ 40,488	87.3 %
65% to 75%	3,931	264	433	4,628	10.0	4,628	10.0
76% to 80%	405	210	56	671	1.5	638	1.4
Greater than 80%	478	176	—	654	1.4	618	1.3
Total	\$44,043	\$ 1,341	\$ 691	\$46,075	100.0%	\$ 46,372	100.0%
December 31, 2017							
Loan-to-value ratios:							
Less than 65%	\$37,073	\$ 1,483	\$ 201	\$38,757	87.4 %	\$ 39,528	87.7 %
65% to 75%	4,183	98	119	4,400	9.9	4,408	9.8
76% to 80%	235	210	57	502	1.1	476	1.0
Greater than 80%	401	168	147	716	1.6	672	1.5
Total	\$41,892	\$ 1,959	\$ 524	\$44,375	100.0%	\$ 45,084	100.0%

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Credit Quality of Agricultural Mortgage Loans

The credit quality of agricultural mortgage loans was as follows at:

	June 30, 2018	December 31, 2017
	Recorded% of Investmenttotal	Recorded% of Investmenttotal
(Dollars in millions)		
Loan-to-value ratios:		
Less than 65%	\$12,576 94.6 %	\$12,347 94.9 %
65% to 75%	676 5.1	618 4.7
76% to 80%	32 0.2	40 0.3
Greater than 80%	9 0.1	9 0.1
Total	\$13,293 100.0%	\$13,014 100.0%

The estimated fair value of agricultural mortgage loans was \$13.2 billion and \$13.1 billion at June 30, 2018 and December 31, 2017, respectively.

Credit Quality of Residential Mortgage Loans

The credit quality of residential mortgage loans was as follows at:

	June 30, 2018	December 31, 2017
	Recorded% of Investmenttotal	Recorded% of Investmenttotal
(Dollars in millions)		
Performance indicators:		
Performing	\$10,945 96.0 %	\$10,622 95.4 %
Nonperforming	459 4.0	514 4.6
Total	\$11,404 100.0%	\$11,136 100.0%

The estimated fair value of residential mortgage loans was \$11.7 billion and \$11.6 billion at June 30, 2018 and December 31, 2017, respectively.

Past Due and Nonaccrual Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 99% of all mortgage loans classified as performing at both June 30, 2018 and December 31, 2017. The Company defines delinquency consistent with industry practice, when mortgage loans are past due as follows: commercial and residential mortgage loans — 60 days and agricultural mortgage loans — 90 days. The past due and nonaccrual mortgage loans at recorded investment, prior to valuation allowances, by portfolio segment, were as follows at:

Past Due	Greater than 90 Days Past Due and Still Accruing Interest		Nonaccrual	
	June 30, 2018	December 31, 2017	June 30, 2018	December 31, 2017
(In millions)				
Commercial	\$1	\$ —	\$176	\$ —
Agricultural	233	134	107	36
Residential	459	514	428	481
Total	\$693	\$ 648	\$711	\$ 517

Cash Equivalents

The carrying value of cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was \$9.4 billion and \$6.2 billion at June 30, 2018 and December 31, 2017, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Net Unrealized Investment Gains (Losses)

Unrealized investment gains (losses) on fixed maturity securities AFS and equity securities and the effect on DAC, VOBA, deferred sales inducements (“DSI”), future policy benefits and the policyholder dividend obligation, that would result from the realization of the unrealized gains (losses), are included in net unrealized investment gains (losses) in AOCI.

The components of net unrealized investment gains (losses), included in AOCI, were as follows:

	June 30, 2018	December 31, 2017
	(In millions)	
Fixed maturity securities	\$13,918	\$ 22,645
Fixed maturity securities with noncredit OTTI losses included in AOCI	34	41
Total fixed maturity securities	13,952	22,686
Equity securities	—	421
Derivatives	1,547	1,453
Other	112	46
Subtotal	15,611	24,606
Amounts allocated from:		
Future policy benefits	(132)	(77)
DAC, VOBA and DSI	(1,156)	(1,768)
Policyholder dividend obligation	(792)	(2,121)
Subtotal	(2,080)	(3,966)
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI	(5)	(12)
Deferred income tax benefit (expense)	(3,814)	(6,958)
Net unrealized investment gains (losses)	9,712	13,670
Net unrealized investment gains (losses) attributable to noncontrolling interests	(9)	(8)
Net unrealized investment gains (losses) attributable to MetLife, Inc.	\$9,703	\$ 13,662

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The changes in net unrealized investment gains (losses) were as follows:

	Six Months Ended June 30, 2018 (In millions)
Balance, beginning of period	\$ 13,662
Cumulative effects of changes in accounting principles, net of income tax (Note 1)	1,258
Fixed maturity securities on which noncredit OTTI losses have been recognized	(7)
Unrealized investment gains (losses) during the period	(8,563)
Unrealized investment gains (losses) relating to:	
Future policy benefits	(55)
DAC, VOBA and DSI	612
Policyholder dividend obligation	1,329
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI	7
Deferred income tax benefit (expense)	1,461
Net unrealized investment gains (losses)	9,704
Net unrealized investment gains (losses) attributable to noncontrolling interests	(1)
Balance, end of period	\$ 9,703
Change in net unrealized investment gains (losses)	\$ (3,958)
Change in net unrealized investment gains (losses) attributable to noncontrolling interests	(1)
Change in net unrealized investment gains (losses) attributable to MetLife, Inc.	\$ (3,959)

Concentrations of Credit Risk

Investments in any counterparty that were greater than 10% of the Company's equity, other than the U.S. government and its agencies, were in fixed income securities of the Japanese government and its agencies with an estimated fair value of \$29.7 billion and \$27.5 billion at June 30, 2018 and December 31, 2017, respectively, and in fixed income securities of the South Korean government and its agencies with an estimated fair value of \$6.4 billion and \$6.5 billion at June 30, 2018 and December 31, 2017, respectively.

Securities Lending

Elements of the Company's securities lending program are presented below at:

	June 30, December 31, 2018 2017 (In millions)
Securities on loan: (1)	
Amortized cost	\$18,052 \$ 17,801
Estimated fair value	\$18,846 \$ 19,028
Cash collateral received from counterparties (2)	\$19,244 \$ 19,417
Security collateral received from counterparties (3)	\$47 \$ 19
Reinvestment portfolio — estimated fair value	\$19,374 \$ 19,508

(1) Included within fixed maturity securities and cash equivalents.

(2) Included within payables for collateral under securities loaned and other transactions.

(3) Security collateral received from counterparties may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The cash collateral liability by loaned security type and remaining tenor of the agreements was as follows at:

	June 30, 2018			December 31, 2017				
	Remaining Tenor of Securities Lending Agreements			Remaining Tenor of Securities Lending Agreements				
	Open (1)	1 Month or Less	Over 1 to 6 Months	Total	Open (1)	1 Month or Less	Over 1 to 6 Months	Total
(In millions)								
Cash collateral liability by loaned security type:								
U.S. government and agency	\$4,042	\$ 4,274	\$ 9,891	\$ 18,207	\$ 3,753	\$ 6,031	\$ 8,607	\$ 18,391
Foreign government	—	245	717	962	—	192	834	1,026
Agency RMBS	—	75	—	75	—	—	—	—
Total	\$4,042	\$ 4,594	\$ 10,608	\$ 19,244	\$ 3,753	\$ 6,223	\$ 9,441	\$ 19,417

(1) The related loaned security could be returned to the Company on the next business day which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell securities to meet the return obligation, it may have difficulty selling such collateral that is invested in securities in a timely manner, be forced to sell securities in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both. The estimated fair value of the securities on loan related to the cash collateral on open at June 30, 2018 was \$4.0 billion, all of which were U.S. government and agency securities which, if put back to the Company, could be immediately sold to satisfy the cash requirement.

The reinvestment portfolio acquired with the cash collateral consisted principally of fixed maturity securities (including agency RMBS, U.S. government and agency securities, and ABS), cash equivalents and short-term investments, with 62% invested in agency RMBS, U.S. government and agency securities, cash equivalents, short-term investments or held in cash. If the securities on loan or the reinvestment portfolio become less liquid, the Company has the liquidity resources of most of its general account available to meet any potential cash demands when securities on loan are put back to the Company.

Repurchase Agreements

Elements of the Company's short-term repurchase agreements are presented below at:

	June 30, 2018	December 31, 2017
(In millions)		
Securities on loan: (1)		
Amortized cost	\$2,519	\$ 994
Estimated fair value	\$2,622	\$ 1,141
Cash collateral received from counterparties (2)	\$2,560	\$ 1,102
Reinvestment portfolio — estimated fair value	\$2,568	\$ 1,102

(1) Included within fixed maturity securities, cash equivalents and short-term investments.

(2) Included within payables for collateral under securities loaned and other transactions and other liabilities.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The cash collateral liability by loaned security type and remaining tenor of the agreements was as follows at:

June 30, 2018			December 31, 2017		
Remaining Tenor of Repurchase Agreements			Remaining Tenor of Repurchase Agreements		
1 Month or Less	Over 1 to 6 Months	Total	1 Month or Less	Over 1 to 6 Months	Total
(In millions)					

Cash collateral liability by loaned security type:

U.S. government and agency	\$2,465	\$ —	\$2,465	\$1,005	\$ —	\$1,005
All other corporate and government	44	51	95	44	53	97
Total	\$2,509	\$ 51	\$2,560	\$1,049	\$ 53	\$1,102

The reinvestment portfolio acquired with the cash collateral consisted principally of fixed maturity securities (including U.S. government and agency securities, agency RMBS, ABS and U.S. corporate securities) and cash equivalents, with 65% invested in U.S. government and agency securities, agency RMBS, cash equivalents, short-term investments, or held in cash. If the securities on loan or the reinvestment portfolio become less liquid, the Company has the liquidity resources of most of its general account available to meet any potential cash demands when securities on loan are put back to the Company.

FHLB of Boston Advance Agreements

At June 30, 2018 and December 31, 2017, a subsidiary of the Company had pledged fixed maturity securities with an estimated fair value of \$1.3 billion and \$564 million, respectively, as collateral and received \$800 million and \$300 million, respectively, in cash advances under short-term advance agreements with the FHLB of Boston. The liability to return the cash advances is included within payables for collateral under securities loaned and other transactions. The estimated fair value of the reinvestment portfolio acquired with the cash advances was \$806 million and \$300 million at June 30, 2018 and December 31, 2017, respectively, and consisted primarily of U.S. government and agency fixed maturity securities and Structured Securities. The subsidiary is permitted to withdraw any portion of the pledged collateral over the minimum collateral requirement at any time, other than in the event of a default by the subsidiary.

The cash advance liability by loaned security type and remaining tenor of the agreements was as follows at:

June 30, 2018			December 31, 2017				
Remaining Tenor of Advance Agreements			Remaining Tenor of Advance Agreements				
1 Month or Less	Over 1 to 6 Months	6 Months to 1 Year	Total	1 Month or Less	Over 1 to 6 Months	6 Months to 1 Year	Total
(In millions)							

Cash advance liability by loaned security type:

State and political subdivision	\$100	\$ 625	\$ 75	\$800	\$—	\$ 300	\$ —	\$—300
Invested Assets on Deposit, Held in Trust and Pledged as Collateral								

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value, at:

	June 30, December 31,	
	2018	2017
	(In millions)	
Invested assets on deposit (regulatory deposits)	\$1,804	\$ 1,879
Invested assets held in trust (collateral financing arrangement and reinsurance agreements)	3,100	2,490
Invested assets pledged as collateral	24,808	24,174
Total invested assets on deposit, held in trust and pledged as collateral	\$29,712	\$ 28,543

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Note 4 of the Notes to the Consolidated Financial Statements included in the 2017 Annual Report) and derivative transactions (see Note 7). Amounts in the table above include invested assets and cash and cash equivalents.

See “— Securities Lending” and “— Repurchase Agreements” for information regarding securities on loan, Note 5 for information regarding investments designated to the closed block and “— Equity Securities” for information on common stock holdings in regional banks of the FHLB system, which are considered restricted investments.

Variable Interest Entities

The Company has invested in legal entities that are VIEs. In certain instances, the Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity. The determination of the VIE’s primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party’s relationship with or involvement in the entity, an estimate of the entity’s expected losses and expected residual returns and the allocation of such estimates to each party involved in the entity.

Consolidated VIEs

Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company, as the Company’s obligation to the VIEs is limited to the amount of its committed investment.

The following table presents the total assets and total liabilities relating to investment-related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at:

	June 30, 2018		December 31, 2017	
	Total Assets	Total Liabilities	Total Assets	Total Liabilities
	(In millions)			
Renewable energy partnership (1)	\$ 109	\$ —	\$ 116	\$ 3
Investment fund (2)	333	1	—	—
Other investments	31	5	32	6
Total	\$473	\$ 6	\$ 148	\$ 9

(1) Assets of the renewable energy partnership primarily consisted of other invested assets.

(2) Assets of the investment fund primarily consisted of other invested assets.

Unconsolidated VIEs

The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at:

	June 30, 2018		December 31, 2017	
	Carrying Amount	Maximum Exposure to Loss (1)	Carrying Amount	Maximum Exposure to Loss (1)
	(In millions)			
Fixed maturity securities AFS:				
Structured Securities (2)	\$46,531	\$ 46,531	\$47,614	\$ 47,614
U.S. and foreign corporate	1,281	1,281	1,560	1,560
Other limited partnership interests	5,088	9,269	4,834	8,543
Other invested assets	1,866	2,080	2,291	2,625
Other investments	37	41	82	87
Total	\$54,803	\$ 59,202	\$56,381	\$ 60,429

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company's return is in the form of income tax credits which are guaranteed by creditworthy third parties.

(1) For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of \$107 million and \$117 million at June 30, 2018 and December 31, 2017, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.

(2) For these variable interests, the Company's involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.

As described in Note 15, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to investees designated as VIEs during both the six months ended June 30, 2018 and 2017.

Net Investment Income

The components of net investment income were as follows:

	Three Months		Six Months	
	Ended		Ended	
	June 30,		June 30,	
	2018	2017	2018	2017
	(In millions)			
Investment income:				
Fixed maturity securities	\$3,014	\$2,839	\$5,910	\$5,664
Equity securities	15	31	31	62
FVO Securities (1)	8	16	14	45
Mortgage loans	815	758	1,607	1,494
Policy loans	127	129	251	256
Real estate and real estate joint ventures	195	169	363	322
Other limited partnership interests	120	194	327	434
Cash, cash equivalents and short-term investments	95	56	167	107
Operating joint ventures	19	5	32	7
Other	94	53	200	125
Subtotal	4,502	4,250	8,902	8,516
Less: Investment expenses	315	271	617	532
Subtotal, net	4,187	3,979	8,285	7,984
Unit-linked investments (1)	286	214	(67)	630
Net investment income	\$4,473	\$4,193	\$8,218	\$8,614

Changes in estimated fair value subsequent to purchase for investments still held as of the end of the respective periods included in net investment income were principally from Unit-linked investments, and were \$165 million and (\$174) million for the three months and six months ended June 30, 2018, respectively, and \$119 million and \$449 million for the three months and six months ended June 30, 2017, respectively.

The Company invests in real estate joint ventures, other limited partnership interests and tax credit and renewable energy partnerships, and also does business through certain operating joint ventures, the majority of which are accounted for under the equity method. Net investment income from other limited partnership interests and operating joint ventures, accounted for under the equity method; and real estate joint ventures and tax credit and renewable energy partnerships, primarily accounted for under the equity method, totaled \$97 million and \$302 million for the

three months and six months ended June 30, 2018, respectively, and \$121 million and \$284 million for the three months and six months ended June 30, 2017, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Net Investment Gains (Losses)

Components of Net Investment Gains (Losses)

The components of net investment gains (losses) were as follows:

	Three Months Ended June 30, 2018		Six Months Ended June 30, 2018	
	2017	2018	2017	2018
	(In millions)			
Total gains (losses) on fixed maturity securities:				
Total OTTI losses recognized — by sector and industry:				
State and political subdivision	\$—	\$(3)	\$—	\$(3)
OTTI losses on fixed maturity securities recognized in earnings	—	(3)	—	(3)
Fixed maturity securities — net gains (losses) on sales and disposals	(46)	45	(141)	43
Total gains (losses) on fixed maturity securities	(46)	42	(141)	40
Total gains (losses) on equity securities:				
OTTI losses recognized — by security type:				
Common stock	—	(5)	—	(12)
Non-redeemable preferred stock	—	—	—	(1)
Total OTTI losses on equity securities recognized in earnings	—	(5)	—	(13)
Equity securities — net gains (losses) on sales and disposals	14	5	116	48
Change in estimated fair value of equity securities (1)	20	—	(113)	—
Total gains (losses) on equity securities	34	—	3	35
Mortgage loans	(15)	(14)	(36)	(26)
Real estate and real estate joint ventures	89	270	114	267
Other limited partnership interests	8	(11)	8	(18)
Other	(58)	(70)	(188)	(96)
Subtotal	12	217	(240)	202
Change in estimated fair value of other limited partnership interests and real estate joint ventures	(1)	—	(6)	—
Non-investment portfolio gains (losses) (2)	(238)	(113)	(314)	(10)
Total net investment gains (losses)	\$(227)	\$104	\$(560)	\$192

Changes in estimated fair value subsequent to purchase for equity securities still held as of the end of the period (1) included in net investment gains (losses) were \$31 million and (\$5) million for the three months and six months ended June 30, 2018, respectively. See Note 1.

Non-investment portfolio gains (losses) for the three months and six months ended June 30, 2018 includes a loss of (2)\$159 million and \$327 million, respectively, which represents both the change in estimated fair value of FVO

Brighthouse Common Stock held by the Company through date of disposal and the loss on disposal. See Note 3. Gains (losses) from foreign currency transactions included within net investment gains (losses) were (\$47) million and \$18 million for the three months and six months ended June 30, 2018, respectively, and (\$118) million and (\$38) million for the three months and six months ended June 30, 2017, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Sales or Disposals and Impairments of Fixed Maturity Securities AFS

Investment gains and losses on sales of securities are determined on a specific identification basis. Proceeds from sales or disposals of fixed maturity securities AFS and the components of fixed maturity securities AFS net investment gains (losses) were as shown in the table below:

	Three Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	2018	2017	2018	2017
	(In millions)			
Proceeds	\$20,183	\$12,486	\$39,253	\$26,947
Gross investment gains	\$149	\$117	\$255	\$259
Gross investment losses	(195)	(72)	(396)	(216)
OTTI losses	—	(3)	—	(3)
Net investment gains (losses)	\$(46)	\$42	\$(141)	\$40

Credit Loss Rollforward

The table below presents a rollforward of the cumulative credit loss component of OTTI loss recognized in earnings on fixed maturity securities still held for which a portion of the OTTI loss was recognized in other comprehensive income (loss) (“OCI”):

	Three Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	2018	2017	2018	2017
	(In millions)			
Balance, beginning of period	\$128	\$170	\$138	\$187
Sales (maturities, pay downs or prepayments) of securities previously impaired as credit loss OTTI	(17)	(5)	(26)	(22)
Increase in cash flows — accretion of previous credit loss OTTI	—	—	(1)	—
Balance, end of period	\$111	\$165	\$111	\$165

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives

Accounting for Derivatives

Freestanding Derivatives

Freestanding derivatives are carried on the Company's balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement.

Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivative's carrying value in other invested assets or other liabilities.

If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows:

Statement of Operations Presentation: Derivative:

Policyholder benefits and claims	• Economic hedges of variable annuity guarantees included in future policy benefits
Net investment income	• Economic hedges of equity method investments in joint ventures • Derivatives held within Unit-linked investments

Hedge Accounting

To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows:

Fair value hedge (a hedge of the estimated fair value of a recognized asset or liability) - in net derivative gains (losses), consistent with the change in estimated fair value of the hedged item attributable to the designated risk being hedged.

Cash flow hedge (a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability) - effectiveness in OCI (deferred gains or losses on the derivative are reclassified into the statement of operations when the Company's earnings are affected by the variability in cash flows of the hedged item); ineffectiveness in net derivative gains (losses).

Net investment in a foreign operation hedge - effectiveness in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation; ineffectiveness in net derivative gains (losses).

The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item. Accruals on derivatives in net investment hedges are recognized in OCI.

In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument's effectiveness and the method that will be used to measure ineffectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness and measurements of ineffectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income.

The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. Provided the hedged forecasted transaction is still probable of occurrence, the changes in estimated fair value of derivatives recorded in OCI related to discontinued cash flow hedges are released into the statement of operations when the Company's earnings are affected by the variability in cash flows of the hedged item.

When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses).

Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable are recognized immediately in net derivative gains (losses).

In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses).

Embedded Derivatives

The Company sells variable annuities and issues certain insurance products and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if:

- the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;

- the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and

- a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.

Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are generally reported in net derivative gains (losses). If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent "excess" fees and are reported in universal life and investment-type product policy fees.

See Note 8 for information about the fair value hierarchy for derivatives.

Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives.

Derivatives are financial instruments with values derived from interest rates, foreign currency exchange rates, credit spreads and/or other financial indices. Derivatives may be exchange-traded or contracted in the over-the-counter ("OTC") market. Certain of the Company's OTC derivatives are cleared and settled through central

clearing counterparties (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The types of derivatives the Company uses include swaps, forwards, futures and option contracts. To a lesser extent, the Company uses credit default swaps and structured interest rate swaps to synthetically replicate investment risks and returns which are not readily available in the cash markets.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Interest Rate Derivatives

The Company uses a variety of interest rate derivatives to reduce its exposure to changes in interest rates, including interest rate swaps, interest rate total return swaps, caps, floors, swaptions, futures and forwards.

Interest rate swaps are used by the Company primarily to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). In an interest rate swap, the Company agrees with another party to exchange, at specified intervals, the difference between fixed rate and floating rate interest amounts as calculated by reference to an agreed notional amount. The Company utilizes interest rate swaps in fair value, cash flow and nonqualifying hedging relationships.

The Company uses structured interest rate swaps to synthetically create investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and a cash instrument such as a U.S. government and agency, or other fixed maturity security. Structured interest rate swaps are included in interest rate swaps and are not designated as hedging instruments.

Interest rate total return swaps are swaps whereby the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and the London Interbank Offered Rate (“LIBOR”), calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. These transactions are entered into pursuant to master agreements that provide for a single net payment to be made by the counterparty at each due date. Interest rate total return swaps are used by the Company to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). The Company utilizes interest rate total return swaps in nonqualifying hedging relationships.

The Company purchases interest rate caps primarily to protect its floating rate liabilities against rises in interest rates above a specified level, and against interest rate exposure arising from mismatches between assets and liabilities, and interest rate floors primarily to protect its minimum rate guarantee liabilities against declines in interest rates below a specified level. In certain instances, the Company locks in the economic impact of existing purchased caps and floors by entering into offsetting written caps and floors. The Company utilizes interest rate caps and floors in nonqualifying hedging relationships.

In exchange-traded interest rate (Treasury and swap) futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of interest rate securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange.

Exchange-traded interest rate (Treasury and swap) futures are used primarily to hedge mismatches between the duration of assets in a portfolio and the duration of liabilities supported by those assets, to hedge against changes in value of securities the Company owns or anticipates acquiring, to hedge against changes in interest rates on anticipated liability issuances by replicating Treasury or swap curve performance, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded interest rate futures in nonqualifying hedging relationships.

Swaptions are used by the Company to hedge interest rate risk associated with the Company’s long-term liabilities and invested assets. A swaption is an option to enter into a swap with a forward starting effective date. In certain instances, the Company locks in the economic impact of existing purchased swaptions by entering into offsetting written swaptions. The Company pays a premium for purchased swaptions and receives a premium for written swaptions. The Company utilizes swaptions in nonqualifying hedging relationships. Swaptions are included in interest rate options. The Company enters into interest rate forwards to buy and sell securities. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. The Company utilizes interest rate forwards in cash flow and nonqualifying hedging relationships.

A synthetic guaranteed interest contract (“GIC”) is a contract that simulates the performance of a traditional GIC through the use of financial instruments. Under a synthetic GIC, the contractholder owns the underlying assets. The Company guarantees a rate of return on those assets for a premium. Synthetic GICs are not designated as hedging instruments.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Foreign Currency Exchange Rate Derivatives

The Company uses foreign currency exchange rate derivatives, including foreign currency swaps, foreign currency forwards, currency options and exchange-traded currency futures, to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets and liabilities denominated in foreign currencies. The Company also uses foreign currency derivatives to hedge the foreign currency exchange rate risk associated with certain of its net investments in foreign operations.

In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company utilizes foreign currency swaps in fair value, cash flow and nonqualifying hedging relationships.

In a foreign currency forward transaction, the Company agrees with another party to deliver a specified amount of an identified currency at a specified future date. The price is agreed upon at the time of the contract and payment for such a contract is made at the specified future date. The Company utilizes foreign currency forwards in fair value, net investment in foreign operations and nonqualifying hedging relationships.

The Company enters into currency options that give it the right, but not the obligation, to sell the foreign currency amount in exchange for a functional currency amount within a limited time at a contracted price. The contracts may also be net settled in cash, based on differentials in the foreign currency exchange rate and the strike price. The Company uses currency options to hedge against the foreign currency exposure inherent in certain of its variable annuity products. The Company also uses currency options as an economic hedge of foreign currency exposure related to the Company's international subsidiaries. The Company utilizes currency options in net investment in foreign operations and nonqualifying hedging relationships.

To a lesser extent, the Company uses exchange-traded currency futures to hedge currency mismatches between assets and liabilities, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded currency futures in nonqualifying hedging relationships.

Credit Derivatives

The Company enters into purchased credit default swaps to hedge against credit-related changes in the value of its investments. In a credit default swap transaction, the Company agrees with another party to pay, at specified intervals, a premium to hedge credit risk. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the delivery of par quantities of the referenced investment equal to the specified swap notional amount in exchange for the payment of cash amounts by the counterparty equal to the par value of the investment surrendered. Credit events vary by type of issuer but typically include bankruptcy, failure to pay debt obligations and involuntary restructuring for corporate obligors, as well as repudiation, moratorium or governmental intervention for sovereign obligors. In each case, payout on a credit default swap is triggered only after the Credit Derivatives Determinations Committee of the International Swaps and Derivatives Association, Inc. ("ISDA") deems that a credit event has occurred. The Company utilizes credit default swaps in nonqualifying hedging relationships. The Company enters into written credit default swaps to synthetically create credit investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and one or more cash instruments, such as U.S. government and agency securities, or other fixed maturity securities. These credit default swaps are not designated as hedging instruments.

The Company enters into forwards to lock in the price to be paid for forward purchases of certain securities. The price is agreed upon at the time of the contract and payment for the contract is made at a specified future date. When the primary purpose of entering into these transactions is to hedge against the risk of changes in purchase price due to changes in credit spreads, the Company designates these transactions as credit forwards. The Company utilizes credit forwards in cash flow hedging relationships.

Equity Derivatives

The Company uses a variety of equity derivatives to reduce its exposure to equity market risk, including equity index options, equity variance swaps, exchange-traded equity futures and equity total return swaps.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Equity index options are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. To hedge against adverse changes in equity indices, the Company enters into contracts to sell the underlying equity index within a limited time at a contracted price. The contracts will be net settled in cash based on differentials in the indices at the time of exercise and the strike price. Certain of these contracts may also contain settlement provisions linked to interest rates. In certain instances, the Company may enter into a combination of transactions to hedge adverse changes in equity indices within a pre-determined range through the purchase and sale of options. The Company utilizes equity index options in nonqualifying hedging relationships. Equity variance swaps are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. In an equity variance swap, the Company agrees with another party to exchange amounts in the future, based on changes in equity volatility over a defined period. The Company utilizes equity variance swaps in nonqualifying hedging relationships.

In exchange-traded equity futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of equity securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded equity futures are used primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded equity futures in nonqualifying hedging relationships.

In an equity total return swap, the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and LIBOR, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. The Company uses equity total return swaps to hedge its equity market guarantees in certain of its insurance products. Equity total return swaps can be used as hedges or to synthetically create investments. The Company utilizes equity total return swaps in nonqualifying hedging relationships.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Primary Risks Managed by Derivatives

The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company's derivatives, excluding embedded derivatives, held at:

	Primary Underlying Risk Exposure	June 30, 2018			December 31, 2017		
		Gross Notional Amount	Estimated Assets	Fair Value Liabilities	Gross Notional Amount	Estimated Assets	Fair Value Liabilities
		(In millions)					
Derivatives Designated as Hedging Instruments:							
Fair value hedges:							
Interest rate swaps	Interest rate	\$2,485	\$ 2,074	\$ 1	\$3,843	\$ 2,289	\$ 3
Foreign currency swaps	Foreign currency exchange rate	665	25	—	1,116	50	18
Foreign currency forwards	Foreign currency exchange rate	2,719	6	36	3,253	2	37
Subtotal		5,869	2,105	37	8,212	2,341	58
Cash flow hedges:							
Interest rate swaps	Interest rate	3,490	136	17	3,584	235	4
Interest rate forwards	Interest rate	3,073	—	221	3,332	—	128
Foreign currency swaps	Foreign currency exchange rate	33,713	1,305	1,680	32,152	1,142	1,665
Subtotal		40,276	1,441	1,918	39,068	1,377	1,797
Foreign operations hedges:							
Foreign currency forwards	Foreign currency exchange rate	1,413	39	18	332	2	5
Currency options	Foreign currency exchange rate	8,059	28	237	9,408	44	163
Subtotal		9,472	67	255	9,740	46	168
Total qualifying hedges		55,617	3,613	2,210	57,020	3,764	2,023
Derivatives Not Designated or Not Qualifying as Hedging Instruments:							
Interest rate swaps	Interest rate	53,532	1,547	239	60,485	2,203	576
Interest rate floors	Interest rate	7,201	56	—	7,201	92	—
Interest rate caps	Interest rate	45,375	246	1	53,079	78	2
Interest rate futures	Interest rate	2,715	1	5	4,366	2	4
Interest rate options	Interest rate	23,998	489	—	12,009	656	11
Interest rate forwards	Interest rate	175	—	37	217	—	42
Interest rate total return swaps	Interest rate	1,048	26	—	1,048	8	2
Synthetic GICs	Interest rate	17,184	—	—	11,318	—	—
Foreign currency swaps	Foreign currency exchange rate	12,333	832	435	9,902	693	506
Foreign currency forwards	Foreign currency exchange rate	14,885	123	264	12,238	79	190
Currency futures	Foreign currency exchange rate	869	—	6	846	2	—
Currency options	Foreign currency exchange rate	2,270	15	5	3,123	55	6

Edgar Filing: METLIFE INC - Form 10-Q

Credit default swaps — purchased	Credit	1,948	18	40	2,020	7	43
Credit default swaps — written	Credit	11,836	195	4	11,375	271	—
Equity futures	Equity market	3,272	3	4	4,005	18	4
Equity index options	Equity market	23,207	638	667	19,886	569	690
Equity variance swaps	Equity market	4,661	53	200	4,661	54	199
Equity total return swaps	Equity market	1,014	13	18	1,117	—	41
Total non-designated or nonqualifying derivatives		227,523	4,255	1,925	218,896	4,787	2,316
Total		\$283,140	\$ 7,868	\$ 4,135	\$275,916	\$ 8,551	\$ 4,339

51

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Based on gross notional amounts, a substantial portion of the Company's derivatives was not designated or did not qualify as part of a hedging relationship at both June 30, 2018 and December 31, 2017. The Company's use of derivatives includes (i) derivatives that serve as macro hedges of the Company's exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules; (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship; (iii) derivatives that economically hedge embedded derivatives that do not qualify for hedge accounting because the changes in estimated fair value of the embedded derivatives are already recorded in net income; and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.

Net Derivative Gains (Losses)

The components of net derivative gains (losses) were as follows:

	Three Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	2018	2017	2018	2017
	(In millions)			
Freestanding derivatives and hedging gains (losses) (1)	\$ (210)	\$ (291)	\$ 102	\$ (660)
Embedded derivatives gains (losses)	151	91	188	248
Total net derivative gains (losses)	\$ (59)	\$ (200)	\$ 290	\$ (412)

(1) Includes foreign currency transaction gains (losses) on hedged items in cash flow and nonqualifying hedging relationships, which are not presented elsewhere in this note.

The following table presents earned income on derivatives:

	Three Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	2018	2017	2018	2017
	(In millions)			
Qualifying hedges:				
Net investment income	\$ 93	\$ 70	\$ 174	\$ 145
Interest credited to policyholder account balances	(28)	(14)	(51)	(20)
Other expenses	(4)	(2)	(6)	(5)
Nonqualifying hedges:				
Net derivative gains (losses)	133	146	266	314
Policyholder benefits and claims	3	2	5	4
Total	\$ 197	\$ 202	\$ 388	\$ 438

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Nonqualifying Derivatives and Derivatives for Purposes Other Than Hedging

The following table presents the amount and location of gains (losses) recognized in income for derivatives that were not designated or not qualifying as hedging instruments:

	Net Derivative Gains (Losses) (In millions)	Net Investment Income (1)	Policyholder Benefits and Claims (2)
Three Months Ended June 30, 2018			
Interest rate derivatives	\$(75)	\$ —	\$ (5)
Foreign currency exchange rate derivatives	(1)	—	(5)
Credit derivatives — purchased	14	—	—
Credit derivatives — written	(35)	—	—
Equity derivatives	(174)	—	(33)
Total	\$(271)	\$ —	\$ (43)
Three Months Ended June 30, 2017			
Interest rate derivatives	\$72	\$ (2)	\$ (15)
Foreign currency exchange rate derivatives	(544)	—	2
Credit derivatives — purchased	(7)	—	—
Credit derivatives — written	44	—	—
Equity derivatives	(232)	(1)	(43)
Total	\$(667)	\$ (3)	\$ (56)
Six Months Ended June 30, 2018			
Interest rate derivatives	\$(310)	\$ 4	\$ (12)
Foreign currency exchange rate derivatives	386	—	(3)
Credit derivatives — purchased	11	—	—
Credit derivatives — written	(79)	—	—
Equity derivatives	(76)	1	(21)
Total	\$(68)	\$ 5	\$ (36)
Six Months Ended June 30, 2017			
Interest rate derivatives	\$(318)	\$ —	\$ (13)
Foreign currency exchange rate derivatives	(181)	—	2
Credit derivatives — purchased	(15)	—	—
Credit derivatives — written	76	—	—
Equity derivatives	(586)	(4)	(115)
Total	\$(1,024)	\$ (4)	\$ (126)

(1) Changes in estimated fair value related to economic hedges of equity method investments in joint ventures and derivatives held within Unit-linked investments.

(2) Changes in estimated fair value related to economic hedges of variable annuity guarantees included in future policy benefits.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Fair Value Hedges

The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities; and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments.

The Company recognizes gains and losses on derivatives and the related hedged items in fair value hedges within net derivative gains (losses). The following table presents the amount of such net derivative gains (losses):

54

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

Derivatives in Fair Value Hedging Relationships	Hedged Items in Fair Value Hedging Relationships	Net Derivative Gains (Losses) Recognized for Derivatives	Net Derivative Gains (Losses) Recognized for Hedged Items	Ineffectiveness Recognized in Net Derivative Gains (Losses)
(In millions)				
Three Months Ended June 30, 2018				
Interest rate swaps:	Fixed maturity securities	\$—	\$ —	\$ —
	Policyholder liabilities (1)	(68)	70	2
Foreign currency swaps:	Foreign-denominated fixed maturity securities and mortgage loans	52	(53)	(1)
	Foreign-denominated policyholder account balances (2)	5	(5)	—
Foreign currency forwards:	Foreign-denominated fixed maturity securities	(114)	109	(5)
Total		\$(125)	\$ 121	\$ (4)
Three Months Ended June 30, 2017				
Interest rate swaps:	Fixed maturity securities	\$—	\$ (1)	\$ (1)
	Policyholder liabilities (1)	49	21	70
Foreign currency swaps:	Foreign-denominated fixed maturity securities	(2)	3	1
	Foreign-denominated policyholder account balances (2)	45	(26)	19
Foreign currency forwards:	Foreign-denominated fixed maturity securities	(21)	19	(2)
Total		\$71	\$ 16	\$ 87
Six Months Ended June 30, 2018				
Interest rate swaps:	Fixed maturity securities	\$3	\$ (2)	\$ 1
	Policyholder liabilities (1)	(281)	282	1
Foreign currency swaps:	Foreign-denominated fixed maturity securities and mortgage loans	25	(26)	(1)
	Foreign-denominated policyholder account balances (2)	23	(23)	—
Foreign currency forwards:	Foreign-denominated fixed maturity securities	65	(59)	6
Total		\$(165)	\$ 172	\$ 7
Six Months Ended June 30, 2017				
Interest rate swaps:	Fixed maturity securities	\$1	\$ (2)	\$ (1)
	Policyholder liabilities (1)	(2)	71	69
Foreign currency swaps:	Foreign-denominated fixed maturity securities	(5)	6	1
	Foreign-denominated policyholder account balances (2)	46	(24)	22
Foreign currency forwards:	Foreign-denominated fixed maturity securities	24	(22)	2
Total		\$64	\$ 29	\$ 93

(1) Fixed rate liabilities reported in policyholder account balances or future policy benefits.

(2) Fixed rate or floating rate liabilities.

55

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

For the Company's foreign currency forwards, the change in the estimated fair value of the derivative related to the changes in the difference between the spot price and the forward price is excluded from the assessment of hedge effectiveness. For all other derivatives, all components of each derivative's gain or loss were included in the assessment of hedge effectiveness. For the three months and six months ended June 30, 2018, the component of the change in estimated fair value of derivatives that was excluded from the assessment of hedge effectiveness was (\$12) million and (\$20) million, respectively. For the three months and six months ended June 30, 2017, the component of the change in estimated fair value of derivatives that was excluded from the assessment of hedge effectiveness was (\$17) million and (\$24) million, respectively.

Cash Flow Hedges

The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities; (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments; (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments; and (v) interest rate swaps and interest rate forwards to hedge forecasted fixed-rate borrowings.

In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into net derivative gains (losses). These amounts were \$6 million for both the three months and six months ended June 30, 2018, and \$0 and \$20 million for the three months and six months ended June 30, 2017, respectively.

At June 30, 2018 and December 31, 2017, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed four years and five years, respectively.

At both June 30, 2018 and December 31, 2017, the balance in AOCI associated with cash flow hedges was \$1.5 billion. For the three months and six months ended June 30, 2017, the amount of deferred gains (losses) in AOCI related to Brighthouse derivatives was (\$33) million and (\$52) million, respectively. For the three months and six months ended June 30, 2017, the amount of income reclassified from AOCI into income (loss) from discontinued operations was \$4 million and \$16 million, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivatives (continued)

The following table presents the effects of derivatives in cash flow hedging relationships on the interim condensed consolidated statements of operations and comprehensive income (loss) and the interim condensed consolidated statements of equity. The table excludes the effects of Brighthouse derivatives prior to the Separation.